BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier J-F, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE, Zhang X, Colombel J-F, Kappelman MD. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology. 2020;159:481-491.e483. [PMID: 32425234 DOI: 10.1053/j.gastro.2020.05.032] [Cited by in Crossref: 265] [Cited by in F6Publishing: 269] [Article Influence: 132.5] [Reference Citation Analysis]
Number Citing Articles
1 Liaquat H, Shupp B, Rollins S, Schneider Y, Matin A. Comparison of the impact of chronic corticosteroid therapy on critical care outcomes of COVID-19 patients with and without history of chronic liver disease. Sci Rep 2021;11:19245. [PMID: 34584170 DOI: 10.1038/s41598-021-98778-z] [Reference Citation Analysis]
2 Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, El-Qunni AA, Haile A, Huang K, Kinnett B, Liebeskind MJ, Liu Z, McMorrow LE, Paez D, Perantie DC, Schriefer RE, Sides SE, Thapa M, Gergely M, Abushamma S, Klebert M, Mitchell L, Nix D, Graf J, Taylor KE, Chahin S, Ciorba MA, Katz P, Matloubian M, O'Halloran JA, Presti RM, Wu GF, Whelan SPJ, Buchser WJ, Gensler LS, Nakamura MC, Ellebedy AH, Kim AHJ. Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2. medRxiv 2021:2021. [PMID: 33851176 DOI: 10.1101/2021.04.05.21254656] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 20.0] [Reference Citation Analysis]
3 Pinto S, Loddo E, Paba S, Favale A, Chicco F, Onali S, Usai P, Fantini MC. Crohn's disease and ulcerative colitis patient-reported outcomes signs and symptoms for the remote management of inflammatory bowel disease during the COVID-19 pandemic. J Patient Rep Outcomes 2021;5:48. [PMID: 34165646 DOI: 10.1186/s41687-021-00323-z] [Reference Citation Analysis]
4 Neurath MF. COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34188251 DOI: 10.1038/s41575-021-00480-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Dayem Ullah AZM, Sivapalan L, Kocher HM, Chelala C. COVID-19 in patients with hepatobiliary and pancreatic diseases: a single-centre cross-sectional study in East London. BMJ Open 2021;11:e045077. [PMID: 33875444 DOI: 10.1136/bmjopen-2020-045077] [Reference Citation Analysis]
6 Mahil SK, Dand N, Mason KJ, Yiu ZZN, Tsakok T, Meynell F, Coker B, McAteer H, Moorhead L, Mackenzie T, Rossi MT, Rivera R, Mahe E, Carugno A, Magnano M, Rech G, Balogh EA, Feldman SR, De La Cruz C, Choon SE, Naldi L, Lambert J, Spuls P, Jullien D, Bachelez H, McMahon DE, Freeman EE, Gisondi P, Puig L, Warren RB, Di Meglio P, Langan SM, Capon F, Griffiths CEM, Barker JN, Smith CH; PsoProtect study group. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. J Allergy Clin Immunol 2021;147:60-71. [PMID: 33075408 DOI: 10.1016/j.jaci.2020.10.007] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 19.5] [Reference Citation Analysis]
7 Vogel F, Reincke M. Endocrine risk factors for COVID-19: Endogenous and exogenous glucocorticoid excess. Rev Endocr Metab Disord 2021. [PMID: 34241765 DOI: 10.1007/s11154-021-09670-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Tam LS, Tanaka Y, Handa R, Li Z, Lorenzo JP, Louthrenoo W, Hill C, Pile K, Robinson PC, Dans LF, Hsu LY, Lee SM, Cho J, Hasan ATMT, Salim B, Samreen S, Shaharir SS, Wong P, Chau J, Danda D, Haq SA. Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. Int J Rheum Dis 2021;24:733-45. [PMID: 33945214 DOI: 10.1111/1756-185X.14124] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Goffin E, Candellier A, Vart P, Noordzij M, Arnol M, Covic A, Lentini P, Malik S, Reichert LJ, Sever MS, Watschinger B, Jager KJ, Gansevoort RT; ERACODA Collaborators. COVID-19 related mortality in kidney transplant and hemodialysis patients: a comparative, prospective registry based study. Nephrol Dial Transplant 2021:gfab200. [PMID: 34132811 DOI: 10.1093/ndt/gfab200] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Mocciaro F, Scimeca D, Di Mitri R. The Courage to Return to Everyday Life at the Time of COVID-19: The Point of View of Inflammatory Bowel Disease Patients Needing Endoscopy. Gastroenterology 2021;160:1873-4. [PMID: 32621904 DOI: 10.1053/j.gastro.2020.06.086] [Reference Citation Analysis]
11 Anjum MR, Chalmers J, Hamid R, Rajoriya N. COVID-19: Effect on gastroenterology and hepatology service provision and training: Lessons learnt and planning for the future. World J Gastroenterol 2021; 27(44): 7625-7648 [PMID: 34908803 DOI: 10.3748/wjg.v27.i44.7625] [Reference Citation Analysis]
12 Queiroz NSF, Teixeira FV, Motta MP, Chebli LA, Hino AAF, Martins CA, Quaresma AB, Silva AAPD, Damião AOMC, Saad-Hossne R, Kotze PG. Risk stratification and geographical mapping of Brazilian inflammatory bowel disease patients during the COVID-19 outbreak: Results from a nationwide survey. World J Gastroenterol 2021; 27(12): 1226-1239 [PMID: 33828396 DOI: 10.3748/wjg.v27.i12.1226] [Reference Citation Analysis]
13 Ricciuto A, Lamb CA, Benchimol EI, Walker GJ, Kennedy NA, Kuenzig ME, Kaplan GG, Kappelman MD, Ungaro RC, Colombel JF, Brenner EJ, Agrawal M, Reinisch W, Griffiths AM, Sebastian S. Inflammatory Bowel Disease Clinical Activity Is Associated with COVID-19 Severity Especially in Younger Patients. J Crohns Colitis 2021:jjab172. [PMID: 34570886 DOI: 10.1093/ecco-jcc/jjab172] [Reference Citation Analysis]
14 Tavabie OD, Clough J. Gastroenterology 2021: from the heart of the COVID-19 pandemic. Frontline Gastroenterol 2021;12:249-51. [PMID: 33907619 DOI: 10.1136/flgastro-2021-101799] [Reference Citation Analysis]
15 Rao A, Puertolas M, Runde J. COVID-19 and Gastrointestinal and Hepatobiliary Diseases. Pediatr Ann 2021;50:e315-9. [PMID: 34398713 DOI: 10.3928/19382359-20210721-02] [Reference Citation Analysis]
16 Maconi G, Bosetti C, De Monti A, Boyapati RK, Shelton E, Piazza N, Carvalhas Gabrielli AM, Lenti MV, Bezzio C, Ricci C, Greco S, Romeo S, Giangregorio F, Gridavilla D, Tagliani F, Massari A, Pastorelli L, Di Sabatino A, Saibeni S, Alicante S, Ferretti F, Rizzardini G, Galli M, Ardizzone S. Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population. Dig Liver Dis. 2021;53:263-270. [PMID: 33483259 DOI: 10.1016/j.dld.2020.12.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Viganò C, Massironi S, Pirola L, Cristoferi L, Fichera M, Bravo M, Mauri M, Redaelli AE, Dinelli ME, Invernizzi P. COVID-19 in Patients With Inflammatory Bowel Disease: A Single-center Observational Study in Northern Italy.Inflamm Bowel Dis. 2020;26:e138-e139. [PMID: 32949238 DOI: 10.1093/ibd/izaa244] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Puoti MG, Rybak A, Kiparissi F, Gaynor E, Borrelli O. SARS-CoV-2 and the Gastrointestinal Tract in Children. Front Pediatr 2021;9:617980. [PMID: 33692973 DOI: 10.3389/fped.2021.617980] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Bezzio C, Armuzzi A, Furfaro F, Ardizzone S, Milla M, Carparelli S, Orlando A, Caprioli FA, Castiglione F, Viganò C, Ribaldone DG, Zingone F, Monterubbianesi R, Imperatore N, Festa S, Daperno M, Scucchi L, Ferronato A, Pastorelli L, Balestrieri P, Ricci C, Cappello M, Felice C, Fiorino G, Saibeni S; Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD study. Aliment Pharmacol Ther 2021;54:1432-41. [PMID: 34694009 DOI: 10.1111/apt.16663] [Reference Citation Analysis]
20 Fumery M, Matias C, Brochot E. Seroconversion of immunoglobulins to SARS-CoV2 in patients with inflammatory bowel disease patients treated by biologics. J Crohns Colitis 2020:jjaa154. [PMID: 32697842 DOI: 10.1093/ecco-jcc/jjaa154] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Chebli JMF, Queiroz NSF, Damião AOMC, Chebli LA, Costa MHM, Parra RS. How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician. World J Gastroenterol 2021; 27(11): 1022-1042 [PMID: 33776370 DOI: 10.3748/wjg.v27.i11.1022] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
22 Esatoglu SN, Tascilar K, Babaoğlu H, Bes C, Yurttas B, Akar S, Pehlivan O, Akleylek C, Tecer D, Seyahi E, Yuce-Inel T, Alpay-Kanitez N, Bodakci E, Tekgoz E, Colak S, Bolek EC, Koca SS, Kalyoncu U, Icacan OC, Ugurlu S, Oz HE, Hamuryudan V, Hatemi G; Turkish Society for Rheumatology COVID-19 Registry Investigators. COVID-19 Among Patients With Inflammatory Rheumatic Diseases. Front Immunol 2021;12:651715. [PMID: 33936073 DOI: 10.3389/fimmu.2021.651715] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 [DOI: 10.1101/2020.12.12.20247841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Agrawal M, Brenner EJ, Yan Mak JW, Zhang X, Kaplan GG, Ng SC, Reinisch W, Steinwurz F, Lewis JD, Kissous-Hunt M, Modesto I, Ungaro RC, Colombel JF, Kappelman MD. COVID-19 Outcomes Among Racial and Ethnic Minority Individuals With Inflammatory Bowel Disease in the United States. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00599-1. [PMID: 34089848 DOI: 10.1016/j.cgh.2021.05.060] [Reference Citation Analysis]
25 Bilal M, Sawhney MS, Feuerstein JD. Coronavirus disease-2019: implications for the gastroenterologist. Curr Opin Gastroenterol 2021;37:23-9. [PMID: 33074995 DOI: 10.1097/MOG.0000000000000694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
26 Soldevila-Domenech N, Tío L, Llorente-Onaindia J, Martín-García E, Nebot P, de la Torre R, Gurt A, Maldonado R, Monfort J; Covidmar Study Group. COVID-19 Incidence in Patients With Immunomediated Inflammatory Diseases: Influence of Immunosuppressant Treatments. Front Pharmacol 2020;11:583260. [PMID: 33519443 DOI: 10.3389/fphar.2020.583260] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Hong SJ, Katz S. The elderly IBD patient in the modern era: changing paradigms in risk stratification and therapeutic management. Therap Adv Gastroenterol 2021;14:17562848211023399. [PMID: 34276809 DOI: 10.1177/17562848211023399] [Reference Citation Analysis]
28 Chen S, Zhou J, Ou X, Cheng W, Qin Y, Guo Y, Jiang Y. Alimentary system is directly attacked by SARS-COV-2 and further prevents immune dysregulation caused by COVID-19. Int J Clin Pract 2021;75:e13893. [PMID: 33289233 DOI: 10.1111/ijcp.13893] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Sharma E, Meade S, D'Errico F, Pavlidis P, Luber R, Zeki S, Hill K, Duff A, O'Hanlon D, Tripoli S, Stanton A, Caracostea A, Honap S, Reynolds R, Anderson S, Ray S, Mawdsley J, Sanderson J, Samaan MA, Irving PM. The effects of COVID-19 on IBD prescribing and service provision in a UK tertiary centre. GastroHep 2020;2:318-26. [PMID: 33362435 DOI: 10.1002/ygh2.433] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
30 Ghoshal UC, Sahu S, Biswas SN, Singh P, Chaudhary M, Ghoshal U, Tiwari P, Rai S, Mishra SK. Care of inflammatory bowel disease patients during coronavirus disease-19 pandemic using digital health-care technology. JGH Open 2021. [PMID: 33821221 DOI: 10.1002/jgh3.12498] [Reference Citation Analysis]
31 Faye AS, Lee KE, Laszkowska M, Kim J, Blackett JW, McKenney AS, Krigel A, Giles JT, Wang R, Bernstein EJ, Green PHR, Krishnareddy S, Hur C, Lebwohl B. Risk of Adverse Outcomes in Hospitalized Patients With Autoimmune Disease and COVID-19: A Matched Cohort Study From New York City. J Rheumatol 2021;48:454-62. [PMID: 33132221 DOI: 10.3899/jrheum.200989] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
32 Bekic D, Belosic Halle Z. Inflammatory bowel disease and SARS-CoV-2 pandemic: current knowledge and recommendations. Scand J Gastroenterol 2021;56:656-60. [PMID: 33765405 DOI: 10.1080/00365521.2021.1902561] [Reference Citation Analysis]
33 Meredith J, Khedim CA, Henderson P, Wilson DC, Russell RK. Paediatric Inflammatory Multisystem Syndrome Temporally Associated With SARS-CoV-2 [PIMS-TS] in a Patient Receiving Infliximab Therapy for Inflammatory Bowel Disease. J Crohns Colitis 2021;15:687-91. [PMID: 32997749 DOI: 10.1093/ecco-jcc/jjaa201] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
34 Ferreira N, Mikocka-Walus A, van Tilburg MAL, Graff LA, Apputhurai P, Barreiro-de Acosta M, Evertsz FB, Burisch J, Lo B, Petrik M, Trindade IA, Jedel S, Moser G, Mokrowiecka A, Bernstein CN, Dumitrascu D, Ford AC, Stengel A, Gearry R, Knowles SR. The impact of the coronavirus (COVID-19) pandemic on individuals with gastrointestinal disorders: A protocol of an international collaborative study. J Psychosom Res 2021;148:110561. [PMID: 34217956 DOI: 10.1016/j.jpsychores.2021.110561] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Lees CW, Irving PM, Beaugerie L. COVID-19 and IBD drugs: should we change anything at the moment? Gut 2021;70:632-4. [PMID: 33214164 DOI: 10.1136/gutjnl-2020-323247] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Vuppalanchi V, Gelow K, Green K, Vuppalanchi R, Lammert C. Behaviors, symptoms, and outcomes of North American patients with autoimmune hepatitis during the COVID-19 pandemic. J Investig Med 2021:jim-2021-001871. [PMID: 34315800 DOI: 10.1136/jim-2021-001871] [Reference Citation Analysis]
37 Bernstein CN, Singh H, Murthy SK, Nguyen GC, Benchimol EI, Bitton A, Kuenzig ME, Huang JG, Jones JL, Lee K, Targownik LE, Windsor JW, Mukhtar MS, Tandon P, Kaplan GG. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD. J Can Assoc Gastroenterol 2021;4:S34-9. [PMID: 34755037 DOI: 10.1093/jcag/gwab025] [Reference Citation Analysis]
38 Su S, Shen J, Zhu L, Qiu Y, He JS, Tan JY, Iacucci M, Ng SC, Ghosh S, Mao R, Liang J. Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges. Therap Adv Gastroenterol 2020;13:1756284820934626. [PMID: 32595762 DOI: 10.1177/1756284820934626] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
39 LaSalle TJ, Gonye ALK, Freeman SS, Kaplonek P, Gushterova I, Kays KR, Manakongtreecheep K, Tantivit J, Rojas-Lopez M, Russo BC, Sharma N, Thomas MF, Lavin-Parsons KM, Lilly BM, Mckaig BN, Charland NC, Khanna HK, Lodenstein CL, Margolin JD, Blaum EM, Lirofonis PB, Sonny A, Bhattacharyya RP, Parry BA, Goldberg MB, Alter G, Filbin MR, Villani AC, Hacohen N, Sade-Feldman M. Longitudinal characterization of circulating neutrophils uncovers distinct phenotypes associated with disease severity in hospitalized COVID-19 patients. bioRxiv 2021:2021. [PMID: 34642692 DOI: 10.1101/2021.10.04.463121] [Reference Citation Analysis]
40 Heldman MR, Kates OS. COVID-19 in Solid Organ Transplant Recipients: a Review of the Current Literature. Curr Treat Options Infect Dis 2021;:1-16. [PMID: 34220357 DOI: 10.1007/s40506-021-00249-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
41 Howland S, Deuring JJ, Zhou X, Chen Y, Mota LM, Ungaro RC. Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far? Curr Ther Res Clin Exp 2021;95:100639. [PMID: 34334801 DOI: 10.1016/j.curtheres.2021.100639] [Reference Citation Analysis]
42 Sansotta N, Norsa L, Zuin G, Panceri R, Dilillo D, Pozzi E, Giacomo C, Moretti C, Celano R, Nuti F, Sgaramella P, Stefano MD, Salvatore S, Arrigo S, Motta V, D'Antiga L. Children With Inflammatory Bowel Disease in the COVID-19 Main Endemic Focus: The Lombardy Experience. Front Pediatr 2021;9:607285. [PMID: 33968841 DOI: 10.3389/fped.2021.607285] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Soy M, Keser G, Atagündüz P. Pathogenesis and treatment of cytokine storm in COVID-19. Turk J Biol 2021;45:372-89. [PMID: 34803441 DOI: 10.3906/biy-2105-37] [Reference Citation Analysis]
44 Allez M, Fleshner P, Gearry R, Lakatos PL, Rubin DT. Care of the Patient With IBD Requiring Hospitalisation During the COVID-19 Pandemic. J Crohns Colitis. 2020;14:S774-S779. [PMID: 32722757 DOI: 10.1093/ecco-jcc/jjaa150] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
45 Al-Ani AH, Prentice RE, Christensen B. Letter to the Editor: Care of the Patient with IBD Requiring Hospitalisation During the COVID-19 Pandemic. J Crohns Colitis 2020:jjaa183. [PMID: 32929469 DOI: 10.1093/ecco-jcc/jjaa183] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
46 Barnes A, Andrews J, Spizzo P, Mountifield R. Medication adherence and complementary therapy usage in inflammatory bowel disease patients during the coronavirus disease 2019 pandemic. JGH Open 2021;5:585-9. [PMID: 34013059 DOI: 10.1002/jgh3.12537] [Reference Citation Analysis]
47 Serling-Boyd N, D'Silva KM, Hsu TY, Wallwork R, Fu X, Gravallese EM, Jorge AM, Zhang Y, Choi H, Sparks JA, Wallace ZS. Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. Ann Rheum Dis 2021;80:660-6. [PMID: 33257496 DOI: 10.1136/annrheumdis-2020-219279] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
48 Zecher BF, Buescher G, Willemse J, Walmsley M, Taylor A, Leburgue A, Schramm C, Lohse AW, Sebode M. Prevalence of COVID-19 in patients with autoimmune liver disease in Europe: A patient-oriented online survey. United European Gastroenterol J 2021. [PMID: 34105883 DOI: 10.1002/ueg2.12100] [Reference Citation Analysis]
49 Assa A, Benninga MA, Borrelli O, Broekaert I, de Carpi JM, Saccomani MD, Dolinsek J, Mas E, Miele E, Thomson M, Tzivinikos C; Gastrointestinal Committee of ESPGHAN. Gastrointestinal Perspective of Coronavirus Disease 2019 in Children-An Updated Review. J Pediatr Gastroenterol Nutr 2021;73:299-305. [PMID: 34117195 DOI: 10.1097/MPG.0000000000003204] [Reference Citation Analysis]
50 Merad M, Vabret N. Highlights from a year in a pandemic. J Exp Med 2021;218:e20210220. [PMID: 33835146 DOI: 10.1084/jem.20210220] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Derikx LAAP, Lantinga MA, de Jong DJ, van Dop WA, Creemers RH, Römkens TEH, Jansen JM, Mahmmod N, West RL, Tan ACITL, Bodelier AGL, Gorter MHP, Boekema PJ, Halet ERC, Horjus CS, van Dijk MA, Hirdes MMC, Epping Stippel LSM, Jharap B, Lutgens MWMD, Russel MG, Gilissen LPL, Nauta S, van Bodegraven AA, Hoentjen F. Clinical Outcomes of Covid-19 in Patients With Inflammatory Bowel Disease: A Nationwide Cohort Study. J Crohns Colitis 2021;15:529-39. [PMID: 33079178 DOI: 10.1093/ecco-jcc/jjaa215] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
52 Robinson PC, Richards D, Tanner HL, Feldmann M. Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment. Lancet Rheumatol. 2020;2:e653-e655. [PMID: 33521660 DOI: 10.1016/s2665-9913(20)30309-x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 23] [Article Influence: 25.0] [Reference Citation Analysis]
53 FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis 2020:annrheumdis-2020-218310. [PMID: 33268442 DOI: 10.1136/annrheumdis-2020-218310] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
54 Fung M, Babik JM. COVID-19 in Immunocompromised Hosts: What We Know So Far. Clin Infect Dis. 2021;72:340-350. [PMID: 33501974 DOI: 10.1093/cid/ciaa863] [Cited by in Crossref: 95] [Cited by in F6Publishing: 99] [Article Influence: 95.0] [Reference Citation Analysis]
55 Li J, Luo H, Deng G, Chang J, Qiu X, Liu C, Qin B. Multidimensional Evaluation of All-Cause Mortality Risk and Survival Analysis for Hospitalized Patients with COVID-19. Int J Med Sci 2021;18:3140-9. [PMID: 34400884 DOI: 10.7150/ijms.58889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Maclean A, Ashton JJ, Garrick V, Beattie RM, Hansen R. Impact of COVID-19 on the diagnosis, assessment and management of children with inflammatory bowel disease in the UK: implications for practice. BMJ Paediatr Open 2020;4:e000786. [PMID: 34192173 DOI: 10.1136/bmjpo-2020-000786] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Rosiou K, Ong Ming San E, Kumar A, Esquivel K, Almas S, Stokes D, Ng T, Jayasooriya N, Ranasinghe I, Pollok R, Brookes M, Selinger CP. Comparative Outcomes of Budesonide MMX versus Prednisolone for Ulcerative Colitis: Results from a British Retrospective Multi-Centre Real-World Study. J Clin Med 2021;10:4329. [PMID: 34640345 DOI: 10.3390/jcm10194329] [Reference Citation Analysis]
58 Pawar M, Singh M. Systemic steroids and risk of fecal-oral shedding and increased transmission of SARS-CoV-2 in pemphigus cases. Clin Dermatol 2020;38:750-6. [PMID: 33341209 DOI: 10.1016/j.clindermatol.2020.06.006] [Reference Citation Analysis]
59 Kornbluth A, Kissous-Hunt M, George J, Legnani P. Management of Inflammatory Bowel Disease and COVID-19 in New York City 2020: The Epicenter of IBD in the First Epicenter of the Global Pandemic. Inflamm Bowel Dis. 2020;26:1779-1785. [PMID: 32879978 DOI: 10.1093/ibd/izaa212] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Hisamatsu T. Management of inflammatory bowel disease during the COVID-19 pandemic. Immunol Med 2021;:1-8. [PMID: 34530694 DOI: 10.1080/25785826.2021.1978205] [Reference Citation Analysis]
61 Burke KE, Kochar B, Allegretti JR, Winter RW, Lochhead P, Khalili H, Colizzo FP, Hamilton MJ, Chan WW, Ananthakrishnan AN. Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases. Inflamm Bowel Dis 2021;27:155-61. [PMID: 33089863 DOI: 10.1093/ibd/izaa278] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
62 Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, Hart AL, Irving PM, Kok KB, Lamb CA, Limdi JK, Macdonald J, McGovern DP, Mehta SJ, Murray CD, Patel KV, Pollok RC, Raine T, Russell RK, Selinger CP, Smith PJ, Bowden J, McDonald TJ, Lees CW, Sebastian S, Powell N, Ahmad T; Contributors to the CLARITY IBD study. Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.Gut. 2021;70:865-875. [PMID: 33753421 DOI: 10.1136/gutjnl-2021-324388] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 27.0] [Reference Citation Analysis]
63 Tripathi K, Godoy Brewer G, Thu Nguyen M, Singh Y, Saleh Ismail M, Sauk JS, Parian AM, Limketkai BN. COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Inflamm Bowel Dis 2021:izab236. [PMID: 34718595 DOI: 10.1093/ibd/izab236] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Arrigo S, Alvisi P, Banzato C, Bramuzzo M, Celano R, Civitelli F, D'Arcangelo G, Dilillo A, Dipasquale V, Felici E, Fuoti M, Gatti S, Knafelz D, Lionetti P, Mario F, Marseglia A, Martelossi S, Moretti C, Norsa L, Panceri R, Renzo S, Romano C, Romeo E, Strisciuglio C, Martinelli M. Impact of COVID-19 pandemic on the management of paediatric inflammatory bowel disease: An Italian multicentre study on behalf of the SIGENP IBD Group. Dig Liver Dis. 2021;53:283-288. [PMID: 33388247 DOI: 10.1016/j.dld.2020.12.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
65 Wahezi DM, Lo MS, Rubinstein TB, Ringold S, Ardoin SP, Downes KJ, Jones KB, Laxer RM, Pellet Madan R, Mudano AS, Turner AS, Karp DR, Mehta JJ. American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID-19 Pandemic: Version 2. Arthritis Rheumatol 2021;73:e46-59. [PMID: 34114365 DOI: 10.1002/art.41772] [Reference Citation Analysis]
66 Suria C, Bosca-Watts MM, Navarro P, Tosca J, Anton R, Sanahuja A, Revaliente M, Minguez M. Management of patients with Intestinal Bowel Disease and COVID-19: A review of current evidence and future perspectives. Gastroenterol Hepatol 2021:S0210-5705(21)00203-X. [PMID: 34171421 DOI: 10.1016/j.gastrohep.2021.06.005] [Reference Citation Analysis]
67 Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I; REsponses to COVid-19 vaccinE IsRaeli IBD group [RECOVERI]. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology 2021:S0016-5085(21)03701-X. [PMID: 34717923 DOI: 10.1053/j.gastro.2021.10.029] [Reference Citation Analysis]
68 Rocha APD, Atallah ÁN, Pinto ACPN, Rocha-Filho CR, Milby KM, Civile VT, Carvas Junior N, Reis FSA, Ferla LJ, Ramalho GS, Trevisani GFM, Puga MEDS, Trevisani VFM. COVID-19 and patients with immune-mediated inflammatory diseases undergoing pharmacological treatments: a rapid living systematic review. Sao Paulo Med J 2020;138:515-20. [PMID: 33331606 DOI: 10.1590/1516-3180.2020.0421.R2.10092020] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
69 Fagni F, Simon D, Tascilar K, Schoenau V, Sticherling M, Neurath MF, Schett G. COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses. Lancet Rheumatol 2021;3:e724-36. [PMID: 34485930 DOI: 10.1016/S2665-9913(21)00247-2] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
70 Algaba A, Guerra I, Castro S, Bermejo F. SARS-CoV-2 infection in patients with inflammatory bowel disease in the second-third wave and its comparison with data of first wave of pandemic. Gastroenterol Hepatol 2021:S0210-5705(21)00306-X. [PMID: 34774924 DOI: 10.1016/j.gastrohep.2021.11.001] [Reference Citation Analysis]
71 Madhu D, Sharma S, Agarwal A, Saraya A. Special Considerations in the Management of Autoimmune Hepatitis in COVID-19 Hotspots: A Review. J Clin Transl Hepatol 2021;9:568-75. [PMID: 34447687 DOI: 10.14218/JCTH.2021.00001] [Reference Citation Analysis]
72 Creemers RH, Rezazadeh Ardabili A, Jonkers DM, Leers MPG, Romberg-Camps MJ, Pierik MJ, van Bodegraven AA. Severe COVID-19 in inflammatory bowel disease patients in a population-based setting. PLoS One 2021;16:e0258271. [PMID: 34610041 DOI: 10.1371/journal.pone.0258271] [Reference Citation Analysis]
73 Sakuraba A, Luna A, Micic D. Serologic Response to Coronavirus Disease 2019 (COVID-19) Vaccination in Patients With Immune-Mediated Inflammatory Diseases: A Systematic Review and Meta-analysis. Gastroenterology 2022;162:88-108.e9. [PMID: 34599933 DOI: 10.1053/j.gastro.2021.09.055] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. The effect of smoking on COVID-19 severity: A systematic review and meta-analysis. J Med Virol 2021;93:1045-56. [PMID: 32749705 DOI: 10.1002/jmv.26389] [Cited by in Crossref: 55] [Cited by in F6Publishing: 57] [Article Influence: 27.5] [Reference Citation Analysis]
75 Manansala M, Baughman R, Novak R, Judson M, Sweiss N. Management of immunosuppressants in the era of coronavirus disease-2019. Curr Opin Pulm Med 2021;27:176-83. [PMID: 33779588 DOI: 10.1097/MCP.0000000000000770] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Berte' R, Mazza S, Stefanucci MR, Noviello D, Costa S, Ciafardini C, Mileti E, Mapelli M, Pasqualato S, Pinto S, Favale A, Vecchi M, Neurath MF, Atreya R, Fantini MC, Facciotti F, Caprioli F. Seroprevalence of SARS-CoV2 in IBD Patients Treated with Biologic Therapy. J Crohns Colitis 2021;15:864-8. [PMID: 33211810 DOI: 10.1093/ecco-jcc/jjaa237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
77 Winchester N, Calabrese C, Calabrese LH. The Intersection of COVID-19 and Autoimmunity: What is Our Current Understanding? Pathog Immun 2021;6:31-54. [PMID: 33969248 DOI: 10.20411/pai.v6i1.417] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
78 Dolinger MT, Person H, Smith R, Jarchin L, Pittman N, Dubinsky MC, Lai J. Pediatric Crohn Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated With Infliximab. J Pediatr Gastroenterol Nutr. 2020;71:153-155. [PMID: 32452979 DOI: 10.1097/mpg.0000000000002809] [Cited by in Crossref: 58] [Cited by in F6Publishing: 38] [Article Influence: 29.0] [Reference Citation Analysis]
79 Bernstein CN, Ng SC, Banerjee R, Steinwurz F, Shen B, Carbonnel F, Hamid S, Sood A, Yamamoto-Furusho JK, Griffiths A, Benchimol EI, Travis S, Lopes S, Rubin DT, Kaplan GG, Armstrong D, Gearry R;  IBD-Emerging Nations Consortium and the WGO IBD Task Force on COVID-19 . Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey. Inflamm Bowel Dis. 2020;. [PMID: 32793973 DOI: 10.1093/ibd/izaa202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
80 Agrawal M, Brenner EJ, Zhang X, Modesto I, Woolcott J, Ungaro RC, Colombel JF, Kappelman MD. Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry. Inflamm Bowel Dis 2021;27:585-9. [PMID: 33325523 DOI: 10.1093/ibd/izaa303] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
81 Naseer M, Poola S, Dailey FE, Akin H, Tahan V. Implications of COVID-19 for inflammatory bowel disease: Opportunities and challenges amidst the pandemic. World J Meta-Anal 2020; 8(5): 383-399 [DOI: 10.13105/wjma.v8.i5.383] [Reference Citation Analysis]
82 Lee YJ, Kim SE, Park YE, Chang JY, Song HJ, Kim DH, Yang YJ, Kim BC, Lee JG, Yang HC, Choi M, Myung SJ; Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases. [SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID]. Korean J Gastroenterol 2021;78:117-28. [PMID: 34446634 DOI: 10.4166/kjg.2021.110] [Reference Citation Analysis]
83 Harris RJ, Downey L, Smith TR, Cummings JRF, Felwick R, Gwiggner M. Life in lockdown: experiences of patients with IBD during COVID-19. BMJ Open Gastroenterol 2020;7:e000541. [PMID: 33214234 DOI: 10.1136/bmjgast-2020-000541] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
84 Thomas MG, Kumar P, Islam T, Kuht HJ, Sivagnanasithiyar T, Betteridge C, Moorthy A, Kapoor B. Survey on the impact of COVID19 in patients on immunosuppression for ocular and orbital inflammatory disorders. Eur J Ophthalmol 2021;:11206721211008039. [PMID: 33832345 DOI: 10.1177/11206721211008039] [Reference Citation Analysis]
85 Nørgård BM, Zegers FD, Nielsen J, Kjeldsen J. Post COVID-19 hospitalizations in patients with chronic inflammatory diseases - A nationwide cohort study. J Autoimmun 2021;125:102739. [PMID: 34757259 DOI: 10.1016/j.jaut.2021.102739] [Reference Citation Analysis]
86 Agrawal M, Zhang X, Brenner EJ, Ungaro RC, Kappelman MD, Colombel JF. The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry. J Crohns Colitis 2021;15:1877-84. [PMID: 33884425 DOI: 10.1093/ecco-jcc/jjab071] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
87 Attauabi M, Seidelin JB, Felding OK, Wewer MD, Vinther Arp LK, Sarikaya MZ, Egeberg A, Vladimirova N, Bendtsen F, Burisch J. Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies - A Danish population-based cohort study. J Autoimmun 2021;118:102613. [PMID: 33592545 DOI: 10.1016/j.jaut.2021.102613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
88 Hashash JG, Jabak S, Francis FF, Regueiro M. Should We Be Screening for SARS-CoV-2 in IBD Patients Before Initiation of Biologic Therapy? Inflamm Bowel Dis. 2021;27:291-294. [PMID: 32619000 DOI: 10.1093/ibd/izaa173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Miller LE, Bhattacharyya N. Risk of COVID-19 Infection Among Chronic Rhinosinusitis Patients Receiving Oral Corticosteroids. Otolaryngol Head Neck Surg 2021;:1945998211006931. [PMID: 33845681 DOI: 10.1177/01945998211006931] [Reference Citation Analysis]
90 Nørgård BM, Nielsen J, Knudsen T, Nielsen RG, Larsen MD, Jølving LR, Kjeldsen J. Hospitalization for COVID-19 in patients treated with selected immunosuppressant and immunomodulating agents, compared to the general population: A Danish cohort study. Br J Clin Pharmacol 2021;87:2111-20. [PMID: 33098713 DOI: 10.1111/bcp.14622] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
91 Gianfrancesco M, Yazdany J, Robinson PC. Epidemiology and outcomes of novel coronavirus 2019 in patients with immune-mediated inflammatory diseases. Curr Opin Rheumatol 2020;32:434-40. [PMID: 32675715 DOI: 10.1097/BOR.0000000000000725] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
92 Harris C, Harris RJ, Downey L, Gwiggner M. Management of Crohn's disease in an immunosuppressed COVID-19-positive patient: safety-driven prioritisation of nutritional therapy as a bridge to restarting immunosuppression. BMJ Case Rep 2021;14:e239404. [PMID: 33753379 DOI: 10.1136/bcr-2020-239404] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
93 Kumric M, Ticinovic Kurir T, Martinovic D, Zivkovic PM, Bozic J. Impact of the COVID-19 pandemic on inflammatory bowel disease patients: A review of the current evidence. World J Gastroenterol 2021; 27(25): 3748-3761 [PMID: 34321841 DOI: 10.3748/wjg.v27.i25.3748] [Reference Citation Analysis]
94 Marques CDL, Kakehasi AM, Pinheiro MM, Mota LMH, Albuquerque CP, Silva CR, Santos GPJ, Reis-Neto ET, Matos P, Devide G, Dantas A, Giorgi RD, Marinho AO, Valadares LDA, Melo AKG, Ribeiro FM, Ferreira GA, Santos FPS, Ribeiro SLE, Andrade NPB, Yazbek MA, Souza VA, Paiva ES, Azevedo VF, Freitas ABSB, Provenza JR, Toledo RA, Fontenelle S, Carneiro S, Xavier R, Pileggi GCS, Reis APMG. High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry. RMD Open 2021;7:e001461. [PMID: 33510041 DOI: 10.1136/rmdopen-2020-001461] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
95 Mahil SK, Yates M, Langan SM, Yiu ZZN, Tsakok T, Dand N, Mason KJ, McAteer H, Meynell F, Coker B, Vincent A, Urmston D, Vesty A, Kelly J, Lancelot C, Moorhead L, Bachelez H, Bruce IN, Capon F, Contreras CR, Cope AP, De La Cruz C, Di Meglio P, Gisondi P, Hyrich K, Jullien D, Lambert J, Marzo-Ortega H, McInnes I, Naldi L, Norton S, Puig L, Sengupta R, Spuls P, Torres T, Warren RB, Waweru H, Weinman J, Griffiths CEM, Barker JN, Brown MA, Galloway JB, Smith CH; PsoProtect, CORE-UK study groups. Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. Br J Dermatol 2021;185:80-90. [PMID: 33368145 DOI: 10.1111/bjd.19755] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
96 Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, Behrens EM, Ferris A, Kernan KF, Schulert GS, Seo P, Son MBF, Tremoulet AH, Yeung RSM, Mudano AS, Turner AS, Karp DR, Mehta JJ. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2. Arthritis Rheumatol 2021;73:e13-29. [PMID: 33277976 DOI: 10.1002/art.41616] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 41.0] [Reference Citation Analysis]
97 Moriya K, Nishimura N, Namisaki T, Takaya H, Sawada Y, Kawaratani H, Kaji K, Shimozato N, Sato S, Furukawa M, Douhara A, Akahane T, Mitoro A, Yamao J, Yoshiji H. Zinc Administration and Improved Serum Markers of Hepatic Fibrosis in Patients with Autoimmune Hepatitis. J Clin Med 2021;10:2465. [PMID: 34199421 DOI: 10.3390/jcm10112465] [Reference Citation Analysis]
98 Álvaro Gracia JM, Sanchez-Piedra C, Manero J, Ruiz-Lucea ME, López-Vives L, Bohorquez C, Martinez-Barrio J, Bonilla G, Vela P, García-Villanueva MJ, Navío-Marco MT, Pavía M, Galindo M, Erausquin C, Gonzalez-Gay MA, Rua-Figueroa I, Pego-Reigosa JM, Castrejon I, Sanchez-Costa JT, González-Dávila E, Diaz-Gonzalez F; COVIDSER study group. Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study. RMD Open 2021;7:e001925. [PMID: 34887346 DOI: 10.1136/rmdopen-2021-001925] [Reference Citation Analysis]
99 Efe C, Simşek C, Batıbay E, Calışkan AR, Wahlin S. Feasibility of telehealth in the management of autoimmune hepatitis before and during the COVID-19 pandemic. Expert Rev Gastroenterol Hepatol 2020;14:1215-9. [PMID: 32909852 DOI: 10.1080/17474124.2020.1822734] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
100 Schreiber S, Ben-Horin S, Alten R, Westhovens R, Peyrin-Biroulet L, Danese S, Hibi T, Takeuchi K, Magro F, An Y, Kim DH, Yoon S, Reinisch W. Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Adv Ther 2022. [PMID: 34988877 DOI: 10.1007/s12325-021-01990-6] [Reference Citation Analysis]
101 Kridin K, Schonmann Y, Solomon A, Onn E, Bitan DT, Weinstein O, Cohen AD. Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment-a population-based cohort study. Immunol Res 2021. [PMID: 34647194 DOI: 10.1007/s12026-021-09234-z] [Reference Citation Analysis]
102 Kuchi Bhotla H, Balasubramanian B, Meyyazhagan A, Pushparaj K, Easwaran M, Pappusamy M, Alwin Robert A, Arumugam VA, Tsibizova V, Msaad Alfalih A, Aljowaie RM, Saravanan M, Di Renzo GC. Opportunistic mycoses in COVID-19 patients/survivors: Epidemic inside a pandemic. J Infect Public Health 2021;14:1720-6. [PMID: 34700291 DOI: 10.1016/j.jiph.2021.10.010] [Reference Citation Analysis]
103 Kridin K, Schonmann Y, Damiani G, Peretz A, Onn E, Bitan DT, Cohen AD. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study. Dermatol Ther 2021;34:e15003. [PMID: 34033207 DOI: 10.1111/dth.15003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Vinay G. Increased Self-medication with Steroids in Inflammatory Bowel Disease Patients during COVID-19 Pandemic: Time to Optimize Specialized Telemonitoring Services. Euroasian J Hepatogastroenterol 2021;11:103-4. [PMID: 34786366 DOI: 10.5005/jp-journals-10018-1342] [Reference Citation Analysis]
105 Agrawal M, Brenner EJ, Zhang X, Colombel JF, Kappelman MD, Ungaro RC, Gearry RB, Kalpan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Ruemmele FM, Steinwurz F, Underwood FE; SECURE-IBD Advisory Committee including. Physician Practice Patterns in Holding Inflammatory Bowel Disease Medications due to COVID-19, in the SECURE-IBD Registry. J Crohns Colitis 2021;15:860-3. [PMID: 33232456 DOI: 10.1093/ecco-jcc/jjaa243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
106 Lebeau G, Vagner D, Frumence É, Ah-Pine F, Guillot X, Nobécourt E, Raffray L, Gasque P. Deciphering SARS-CoV-2 Virologic and Immunologic Features. Int J Mol Sci 2020;21:E5932. [PMID: 32824753 DOI: 10.3390/ijms21165932] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
107 Queiroz NSF, Martins CA, Quaresma AB, Hino AAF, Steinwurz F, Ungaro RC, Kotze PG. COVID-19 outcomes in patients with inflammatory bowel diseases in Latin America: Results from SECURE-IBD registry. J Gastroenterol Hepatol 2021. [PMID: 34151470 DOI: 10.1111/jgh.15588] [Reference Citation Analysis]
108 Martínez-Taboada VM, López-Hoyos M, Crespo J, Hernández JL. COVID-19 and immune-mediated inflammatory diseases: Why don't our patients get worse? Autoimmun Rev 2020;19:102683. [PMID: 33127600 DOI: 10.1016/j.autrev.2020.102683] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
109 Schulz C, Mayerle J, Lerch MM, Malfertheiner P. [Update 2021: COVID-19 from the perspective of gastroenterology]. Dtsch Med Wochenschr 2021;146:891-3. [PMID: 34256402 DOI: 10.1055/a-1449-4054] [Reference Citation Analysis]
110 Bourgonje AR, van Linschoten RCA, West RL, van Dijk MA, van Leer-Buter CC, Kats-Ugurlu G, Pierik MJ, Festen EAM, Weersma RK, Dijkstra G. Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options. Therap Adv Gastroenterol 2021;14:17562848211012595. [PMID: 33995584 DOI: 10.1177/17562848211012595] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Park YE, Lee YJ, Chang JY, Song HJ, Kim DH, Yang YJ, Kim BC, Lee JG, Yang HC, Choi M, Kim SE, Myung SJ; Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases. [KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement]. Korean J Gastroenterol 2021;78:105-16. [PMID: 34446633 DOI: 10.4166/kjg.2021.112] [Reference Citation Analysis]
112 Geisen UM, Berner DK, Tran F, Sümbül M, Vullriede L, Ciripoi M, Reid HM, Schaffarzyk A, Longardt AC, Franzenburg J, Hoff P, Schirmer JH, Zeuner R, Friedrichs A, Steinbach A, Knies C, Markewitz RD, Morrison PJ, Gerdes S, Schreiber S, Hoyer BF. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis 2021;80:1306-11. [PMID: 33762264 DOI: 10.1136/annrheumdis-2021-220272] [Cited by in Crossref: 56] [Cited by in F6Publishing: 46] [Article Influence: 56.0] [Reference Citation Analysis]
113 Horst S. Covid-19 and Patients with IBD: Who Is at Highest Risk for Severe Complications? Dig Dis Sci 2021. [PMID: 34181167 DOI: 10.1007/s10620-021-07106-y] [Reference Citation Analysis]
114 Rizzello F, Calabrese C, Salice M, Calandrini L, Privitera H, Melotti L, Peruzzi G, Dussias N, Belluzzi A, Scaioli E, Decorato A, Siniscalchi A, Filippone E, Laureti S, Rottoli M, Poggioli G, Gionchetti P. COVID-19 in IBD: The experience of a single tertiary IBD center. Dig Liver Dis. 2021;53:271-276. [PMID: 33451910 DOI: 10.1016/j.dld.2020.12.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
115 Barclay AR, McGuckin C, Hill S, Protheroe S, Batra A. Exit strategies from the COVID-19 lockdown for children and young people receiving home parenteral nutrition (HPN): lessons from the BSPGHAN Intestinal Failure Working Group experience. Frontline Gastroenterol 2021;12:348-53. [PMID: 34249323 DOI: 10.1136/flgastro-2020-101598] [Reference Citation Analysis]
116 Kridin K, Schonmann Y, Weinstein O, Schmidt E, Ludwig RJ, Cohen AD. The risk of COVID-19 in patients with bullous pemphigoid and pemphigus: A population-based cohort study. J Am Acad Dermatol 2021;85:79-87. [PMID: 33744354 DOI: 10.1016/j.jaad.2021.02.087] [Reference Citation Analysis]
117 Fiorino G, Gilardi D, Radice S, Furfaro F, Allocca M, Danese S. Absence of COVID-19 Infection in Patients Accessing IBD Unit at Humanitas, Milan: Implications for Postlockdown Measures. Am J Gastroenterol 2020;115:1719-21. [PMID: 32852334 DOI: 10.14309/ajg.0000000000000829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
118 Ellen Kuenzig M, Windsor JW, Barrett L, Bernstein CN, Bitton A, Carroll MW, Chauhan U, Coward S, Fowler S, Ghia JE, Geist R, Gibson DL, Graff LA, Griffiths AM, Guoxian Huang J, Jones JL, Khanna R, Lakatos PL, Lee K, Mack DR, Marshall JK, Mukhtar MS, Murthy SK, Nguyen GC, Panaccione R, Seow CH, Singh H, Tandon P, Targownik LE, Zelinsky S, Benchimol EI, Kaplan GG. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary. J Can Assoc Gastroenterol 2021;4:S1-9. [PMID: 34755033 DOI: 10.1093/jcag/gwab027] [Reference Citation Analysis]
119 Ferreira-Duarte M, Estevinho MM, Duarte-Araújo M, Magro F, Morato M. Unraveling the Role of ACE2, the Binding Receptor for SARS-CoV-2, in Inflammatory Bowel Disease. Inflamm Bowel Dis 2020;26:1787-95. [PMID: 33064147 DOI: 10.1093/ibd/izaa249] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
120 Alkan G, Emiroglu M, Oz SKT, Ergani AC, Emiroglu HH. Infliximab: A treatment option for multisystem inflammatory syndrome in children with ulcerative colitis? Turk Arch Pediatr 2021;56:267-9. [PMID: 34104920 DOI: 10.5152/TurkArchPediatr.2021.21057] [Reference Citation Analysis]
121 Farkas K, Pigniczki D, Rutka M, Szántó KJ, Resál T, Bor R, Fábián A, Szepes Z, Lázár G, Molnár T. The complex relationship between viruses and inflammatory bowel disease - review and practical advices for the daily clinical decision-making during the SARS-CoV-2 pandemic. Therap Adv Gastroenterol 2021;14:1756284820988198. [PMID: 33953797 DOI: 10.1177/1756284820988198] [Reference Citation Analysis]
122 Benson-Pope SJ, Gearry RB. Editorial: social distancing during the COVID-19 pandemic - IBD patients cannot stay at home forever. Aliment Pharmacol Ther 2020;52:717-8. [PMID: 32886355 DOI: 10.1111/apt.15874] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
123 Sebastian S, Walker GJ, Kennedy NA, Conley TE, Patel KV, Subramanian S, Kent AJ, Segal JP, Brookes MJ, Bhala N, Gonzalez HA, Hicks LC, Mehta SJ, Lamb CA;  PROTECT-ASUC Study Group. Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. Lancet Gastroenterol Hepatol. 2021;6:271-281. [PMID: 33545083 DOI: 10.1016/s2468-1253(21)00016-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
124 Miyoshi J, Matsuura M, Hisamatsu T. Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis. Expert Opin Drug Saf 2021. [PMID: 34511011 DOI: 10.1080/14740338.2021.1980536] [Reference Citation Analysis]
125 Murthy SK, Kuenzig ME, Windsor JW, Ghia JE, Griffiths AM, Panaccione R, Seow CH, Benchimol EI, Bernstein CN, Bitton A, Huang JG, Jones JL, Lee K, Kaplan GG, Mukhtar MS, Tandon P, Targownik LE, Gibson DL. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines-Biology, Current Evidence and Recommendations. J Can Assoc Gastroenterol 2021;4:S54-60. [PMID: 34755040 DOI: 10.1093/jcag/gwab033] [Reference Citation Analysis]
126 Dotan I, Panaccione R, Kaplan GG, O'Morain C, Lindsay JO, Abreu MT. Best Practice Guidance for Adult Infusion Centres during the COVID-19 Pandemic: Report from the COVID-19 International Organization for the Study of IBD [IOIBD] Task Force. J Crohns Colitis. 2020;14:S785-S790. [PMID: 32959882 DOI: 10.1093/ecco-jcc/jjaa147] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
127 Ungaro RC, Kappelman MD, Rubin DT, Colombel JF. COVID-19 and Inflammatory Bowel Disease: Lessons Learned, Practical Recommendations, and Unanswered Questions.Gastroenterology. 2021;160:1447-1451. [PMID: 33387525 DOI: 10.1053/j.gastro.2020.12.042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
128 Nishida Y, Hosomi S, Fujimoto K, Nakata R, Sugita N, Itani S, Nadatani Y, Fukunaga S, Otani K, Tanaka F, Nagami Y, Taira K, Kamata N, Watanabe T, Ohfuji S, Fujiwara Y. Impact of the Lockdown Due to the COVID-19 Pandemic on Patients With Inflammatory Bowel Disease. Front Med (Lausanne) 2021;8:649759. [PMID: 34957131 DOI: 10.3389/fmed.2021.649759] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
129 Cohen RD, Feuerstein JD, Rubin DT. Reply. Gastroenterology 2021;160:2627. [PMID: 33561439 DOI: 10.1053/j.gastro.2021.02.012] [Reference Citation Analysis]
130 Jonny, Violetta L, Kartasasmita AS, Amirullah Roesli RM, Rita C. Pharmacological Treatment Options for Coronavirus Disease-19 in Renal Patients. Int J Nephrol 2021;2021:4078713. [PMID: 34858665 DOI: 10.1155/2021/4078713] [Reference Citation Analysis]
131 Singh S, Khan A, Chowdhry M, Bilal M, Kochhar GS, Clarke K. Risk of Severe Coronavirus Disease 2019 in Patients With Inflammatory Bowel Disease in the United States: A Multicenter Research Network Study. Gastroenterology. 2020;159:1575-1578.e4. [PMID: 32522507 DOI: 10.1053/j.gastro.2020.06.003] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 20.5] [Reference Citation Analysis]
132 Tse F, Moayyedi P, Waschke KA, MacMillan M, Forbes N, Carroll MW, Carman N, Leontiadis GI. COVID-19 Vaccination in Patients With Inflammatory Bowel Disease: Communiqué From the Canadian Association of Gastroenterology. J Can Assoc Gastroenterol 2021;4:49. [PMID: 33644678 DOI: 10.1093/jcag/gwaa046] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
133 Yazdany J. COVID-19 in Rheumatic Diseases: A Research Agenda. Arthritis Rheumatol 2020;72:1596-9. [PMID: 32705748 DOI: 10.1002/art.41447] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
134 Tan LY, Komarasamy TV, Rmt Balasubramaniam V. Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword. Front Immunol 2021;12:742941. [PMID: 34659238 DOI: 10.3389/fimmu.2021.742941] [Reference Citation Analysis]
135 Cao TT, Zhang GQ, Pellegrini E, Zhao Q, Li J, Luo LJ, Pan HQ. COVID-19 and its effects on the digestive system. World J Gastroenterol 2021; 27(24): 3502-3515 [PMID: 34239265 DOI: 10.3748/wjg.v27.i24.3502] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
136 Raiker R, Pakhchanian H, Kavadichanda C, Gupta L, Kardeş S, Ahmed S. Axial spondyloarthritis may protect against poor outcomes in COVID-19: propensity score matched analysis of 9766 patients from a nationwide multi-centric research network. Clin Rheumatol 2021. [PMID: 34837569 DOI: 10.1007/s10067-021-05979-y] [Reference Citation Analysis]
137 Ungaro RC, Agrawal M, Brenner EJ, Zhang X, Colombel JF, Kappelman MD, Reinisch W. New Gastrointestinal Symptoms Are Common in Inflammatory Bowel Disease Patients With COVID-19: Data From an International Registry. Inflamm Bowel Dis 2021:izab184. [PMID: 34320194 DOI: 10.1093/ibd/izab184] [Reference Citation Analysis]
138 El-Dallal M, Saroufim A, Systrom H, Ballou S, Farhoud A, Pasam RT, Gadupudi SS, Osman K, Chaudrey K, Cheifetz A, Feuerstein JD. Assessing the repercussions of COVID-19 pandemic on symptoms, disease management, and emotional well-being in patients with inflammatory bowel disease: a multi-site survey study. Scand J Gastroenterol 2021;:1-9. [PMID: 34894999 DOI: 10.1080/00365521.2021.2013527] [Reference Citation Analysis]
139 Sperger J, Shah KS, Lu M, Zhang X, Ungaro RC, Brenner EJ, Agrawal M, Colombel JF, Kappelman MD, Kosorok MR. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in IBD patients. medRxiv 2021:2021. [PMID: 33501455 DOI: 10.1101/2021.01.15.21249889] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
140 Scribano ML. Why Do Immunosuppressed Patients with Inflammatory Bowel Disease Not Seem to Be at a Higher Risk of COVID-19? Dig Dis Sci. 2020;Online ahead of print. [PMID: 33073335 DOI: 10.1007/s10620-020-06624-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
141 Ludvigsson JF, Axelrad J, Halfvarson J, Khalili H, Larsson E, Lochhead P, Roelstraete B, Simon TG, Söderling J, Olén O. Inflammatory bowel disease and risk of severe COVID-19: A nationwide population-based cohort study in Sweden. United European Gastroenterol J 2021;9:177-92. [PMID: 33704918 DOI: 10.1002/ueg2.12049] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
142 [DOI: 10.1101/2021.03.17.21253848] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
143 Dvornikova KA, Bystrova EY, Churilov LP, Lerner A. Pathogenesis of the inflammatory bowel disease in context of SARS-COV-2 infection. Mol Biol Rep 2021;48:5745-58. [PMID: 34296352 DOI: 10.1007/s11033-021-06565-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
144 Jefremow A, Neurath MF. SARS-CoV-2 Virus Manifestations in the Gastrointestinal Tract: Therapeutic Implications. Visc Med 2021;37:63-9. [PMID: 33693046 DOI: 10.1159/000513180] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
145 Dai W, Lund H, Chen Y, Zhang J, Osinski K, Jones SZ, Kreuziger LB, López JA, Benjamin IJ, Silverstein RL, Zheng Z. Hypertriglyceridemia during hospitalization independently associates with mortality in patients with COVID-19. J Clin Lipidol 2021:S1933-2874(21)00122-7. [PMID: 34470719 DOI: 10.1016/j.jacl.2021.08.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
146 Hamaguchi M, Nojiri T, Okamura T, Hashimoto Y, Hanai A, Narisawa S, Ushigome E, Nakanishi N, Fukui M. Status of online diet management program users in Japan during the 2020 Coronavirus disease 2019 pandemic. J Clin Biochem Nutr 2021;69:305-10. [PMID: 34857994 DOI: 10.3164/jcbn.21-31] [Reference Citation Analysis]
147 Morgulchik N, Athanasopoulou F, Chu E, Lam Y, Kamaly N. Potential therapeutic approaches for targeted inhibition of inflammatory cytokines following COVID-19 infection-induced cytokine storm. Interface Focus 2022;12:20210006. [PMID: 34956607 DOI: 10.1098/rsfs.2021.0006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
148 Kaklamanos A, Belogiannis K, Skendros P, Gorgoulis VG, Vlachoyiannopoulos PG, Tzioufas AG. COVID-19 Immunobiology: Lessons Learned, New Questions Arise. Front Immunol 2021;12:719023. [PMID: 34512643 DOI: 10.3389/fimmu.2021.719023] [Reference Citation Analysis]
149 Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, Behrens EM, Ferris A, Kernan KF, Schulert GS, Seo P, F Son MB, Tremoulet AH, Yeung RSM, Mudano AS, Turner AS, Karp DR, Mehta JJ. American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 1. Arthritis Rheumatol 2020;72:1791-805. [PMID: 32705809 DOI: 10.1002/art.41454] [Cited by in Crossref: 101] [Cited by in F6Publishing: 81] [Article Influence: 50.5] [Reference Citation Analysis]
150 Roy S, Sheikh SZ, Furey TS. A machine learning approach identifies 5-ASA and ulcerative colitis as being linked with higher COVID-19 mortality in patients with IBD. Sci Rep 2021;11:16522. [PMID: 34389789 DOI: 10.1038/s41598-021-95919-2] [Reference Citation Analysis]
151 Miller DC, Sun Y, Chen EM, Arnold BF, Acharya NR. The Association between Noninfectious Uveitis and Coronavirus Disease 2019 Outcomes: An Analysis of United States Claims-Based Data. Ophthalmology 2021:S0161-6420(21)00751-X. [PMID: 34648828 DOI: 10.1016/j.ophtha.2021.10.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Lebwohl B, Larsson E, Söderling J, Roelstraete B, Murray JA, Green PHR, Ludvigsson JF. Risk of Severe Covid-19 in Patients with Celiac Disease: A Population-Based Cohort Study. Clin Epidemiol 2021;13:121-30. [PMID: 33628059 DOI: 10.2147/CLEP.S294391] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
153 Kaplan GG, Underwood FE, Coward S, Agrawal M, Ungaro RC, Brenner EJ, Gearry RB, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Steinwurz F, Zhang X, Kappelman MD, Colombel JF. The Multiple Waves of COVID-19 in Patients With Inflammatory Bowel Disease: A Temporal Trend Analysis. Inflamm Bowel Dis 2022:izab339. [PMID: 35032167 DOI: 10.1093/ibd/izab339] [Reference Citation Analysis]
154 Zingone F, Buda A, Savarino E. Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice. Dig Liver Dis 2020;52:1252-3. [PMID: 33051162 DOI: 10.1016/j.dld.2020.09.020] [Reference Citation Analysis]
155 Caldera F, Balzora S, Hayney MS, Farraye FA, Cross RK. Ensuring High and Equitable COVID-19 Vaccine Uptake Among Patients With IBD. Inflamm Bowel Dis 2021:izab114. [PMID: 34013958 DOI: 10.1093/ibd/izab114] [Reference Citation Analysis]
156 Conti C, Rosa I, Zito L, Grossi L, Efthymakis K, Neri M, Porcelli P. Influence of the COVID-19 Outbreak on Disease Activity and Quality of Life in Inflammatory Bowel Disease Patients. Front Psychiatry 2021;12:664088. [PMID: 33967864 DOI: 10.3389/fpsyt.2021.664088] [Reference Citation Analysis]
157 Grover S, Bond SA, Mansour MK, Friedman S. Management of immunotherapy colitis: Special considerations in the COVID-19 era. Cancer 2020;126:4630-3. [PMID: 32797685 DOI: 10.1002/cncr.33125] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
158 Mackie SL, Brouwer E, Conway R, van der Geest KSM, Mehta P, Mollan SP, Neill L, Putman M, Robinson PC, Sattui SE. Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. Lancet Rheumatol 2021;3:e71-82. [PMID: 33521671 DOI: 10.1016/S2665-9913(20)30386-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
159 Dailey J, Kozhaya L, Dogan M, Hopkins D, Lapin B, Herbst K, Brimacombe M, Grandonico K, Karabacak F, Schreiber J, Liang BT, Salazar JC, Unutmaz D, Hyams JS. Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease. medRxiv 2021:2021. [PMID: 34159338 DOI: 10.1101/2021.06.12.21258810] [Reference Citation Analysis]
160 D'Silva KM, Jorge A, Cohen A, McCormick N, Zhang Y, Wallace ZS, Choi HK. COVID-19 Outcomes in Patients With Systemic Autoimmune Rheumatic Diseases Compared to the General Population: A US Multicenter, Comparative Cohort Study. Arthritis Rheumatol 2021;73:914-20. [PMID: 33305544 DOI: 10.1002/art.41619] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 19.0] [Reference Citation Analysis]
161 Caron B, Arondel Y, Reimund JM. COVID-19 and Inflammatory Bowel Disease: Questions on Incidence, Severity, and Impact of Treatment? Clin Gastroenterol Hepatol 2020;18:2637-8. [PMID: 32522559 DOI: 10.1016/j.cgh.2020.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
162 Amigues I, Pearlman AH, Patel A, Reid P, Robinson PC, Sinha R, Kim AH, Youngstein T, Jayatilleke A, Konig M. Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. Expert Rev Clin Immunol 2020;16:1185-204. [PMID: 33146561 DOI: 10.1080/1744666X.2021.1847084] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 6.5] [Reference Citation Analysis]
163 Brenner EJ, Pigneur B, Focht G, Zhang X, Ungaro RC, Colombel JF, Turner D, Kappelman MD, Ruemmele FM. Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases. Clin Gastroenterol Hepatol 2021; 19: 394-396. e5. [PMID: 33059040 DOI: 10.1016/j.cgh.2020.10.010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
164 Kuroda N. Epilepsy and COVID-19: Updated evidence and narrative review. Epilepsy Behav 2021;116:107785. [PMID: 33515934 DOI: 10.1016/j.yebeh.2021.107785] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
165 Ungaro RC, Agrawal M, Park S, Hirten R, Colombel JF, Twyman K, Gulko PS, Klang E. Autoimmune and Chronic Inflammatory Disease Patients with COVID-19. ACR Open Rheumatol 2021;3:111-5. [PMID: 33527691 DOI: 10.1002/acr2.11221] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
166 Din AU, Mazhar M, Waseem M, Ahmad W, Bibi A, Hassan A, Ali N, Gang W, Qian G, Ullah R, Shah T, Ullah M, Khan I, Nisar MF, Wu J. SARS-CoV-2 microbiome dysbiosis linked disorders and possible probiotics role. Biomed Pharmacother. 2021;133:110947. [PMID: 33197765 DOI: 10.1016/j.biopha.2020.110947] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
167 Cheema M, Mitrev N, Hall L, Tiongson M, Ahlenstiel G, Kariyawasam V. Depression, anxiety and stress among patients with inflammatory bowel disease during the COVID-19 pandemic: Australian national survey. BMJ Open Gastroenterol 2021;8:e000581. [PMID: 33579729 DOI: 10.1136/bmjgast-2020-000581] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
168 Jeny F, Lhote R, Lorillon G, Belhomme N, Pugnet G, Borie R, Justet A, Jouneau S, Freymond N, Mekinian A, Dhote R, Tandjaoui-Lambiotte Y, Saindenberg N, Gazengel P, Hervier B, Haroche J, Mathian A, Hié M, Chazal T, Taieb D, Uzunhan Y, Le Pavec J, Annesi-Maesano I, Bergot E, Tazi A, Amoura Z, Valeyre D, Nunes H, Cohen-Aubart F. Correspondence on 'Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis'. Ann Rheum Dis 2020:annrheumdis-2020-218957. [PMID: 33004334 DOI: 10.1136/annrheumdis-2020-218957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
169 Boettler T, Marjot T, Newsome PN, Mondelli MU, Maticic M, Cordero E, Jalan R, Moreau R, Cornberg M, Berg T. Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 mo of the pandemic. JHEP Rep. 2020;2:100169. [PMID: 32835190 DOI: 10.1016/j.jhepr.2020.100169] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 21.0] [Reference Citation Analysis]
170 El Ouali S, Rubin DT, Cohen BL, Regueiro MD, Rieder F. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic. Curr Opin Gastroenterol 2021;37:313-9. [PMID: 33859104 DOI: 10.1097/MOG.0000000000000741] [Reference Citation Analysis]
171 Asdaq SMB, Rajan A, Damodaran A, Kamath SR, Nair KS, Zachariah SM, Sahu RK, Fattepur S, Sreeharsha N, Nair A, Jacob S, Albahrani HA, Alkhaldi EH, Mohzari Y, Alrashed AA, Imran M. Identifying Mucormycosis Severity in Indian COVID-19 Patients: A Nano-Based Diagnosis and the Necessity for Critical Therapeutic Intervention. Antibiotics (Basel) 2021;10:1308. [PMID: 34827246 DOI: 10.3390/antibiotics10111308] [Reference Citation Analysis]
172 Weidinger C, Hegazy AN, Glauben R, Siegmund B. COVID-19-from mucosal immunology to IBD patients. Mucosal Immunol 2021;14:566-73. [PMID: 33608656 DOI: 10.1038/s41385-021-00384-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Efe C, Lammert C, Taşçılar K, Dhanasekaran R, Ebik B, Higuera-de la Tijera F, Calışkan AR, Peralta M, Gerussi A, Massoumi H, Catana AM, Purnak T, Rigamonti C, Aldana AJG, Khakoo N, Nazal L, Frager S, Demir N, Irak K, Melekoğlu-Ellik Z, Kacmaz H, Balaban Y, Atay K, Eren F, Alvares-da-Silva MR, Cristoferi L, Urzua Á, Eşkazan T, Magro B, Snijders R, Barutçu S, Lytvyak E, Zazueta GM, Demirezer-Bolat A, Aydın M, Heurgue-Berlot A, De Martin E, Ekin N, Yıldırım S, Yavuz A, Bıyık M, Narro GC, Kıyıcı M, Akyıldız M, Kahramanoğlu-Aksoy E, Vincent M, Carr RM, Günşar F, Reyes EC, Harputluoğlu M, Aloman C, Gatselis NK, Üstündağ Y, Brahm J, Vargas NCE, Güzelbulut F, Garcia SR, Aguirre J, Anders M, Ratusnu N, Hatemi I, Mendizabal M, Floreani A, Fagiuoli S, Silva M, Idilman R, Satapathy SK, Silveira M, Drenth JPH, Dalekos GN, N Assis D, Björnsson E, Boyer JL, Yoshida EM, Invernizzi P, Levy C, Montano-Loza AJ, Schiano TD, Ridruejo E, Wahlin S. Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis. Liver Int 2021. [PMID: 34846800 DOI: 10.1111/liv.15121] [Reference Citation Analysis]
174 Targownik LE, Bernstein CN, Lakatos PL, Murthy SK, Benchimol EI, Bitton A, Huang JG, Kuenzig ME, Jones JL, Kaplan GG, Lee K, Mukhtar MS, Tandon P, Windsor JW, Panaccione R. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Risk Factors and Medications. J Can Assoc Gastroenterol 2021;4:S40-5. [PMID: 34755038 DOI: 10.1093/jcag/gwab032] [Reference Citation Analysis]
175 Shehab M, Abu-Farha M, Alrashed F, Alfadhli A, Alotaibi K, Alsahli A, Alphonse Thanaraj T, Channanath A, Ali H, Abubaker J, Almulla F. Immunogenicity of BNT162b2 Vaccine in Patients with Inflammatory Bowel Disease on Infliximab Combination Therapy: A Multicenter Prospective Study. J Clin Med 2021;10:5362. [PMID: 34830644 DOI: 10.3390/jcm10225362] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
176 Richards GA, Feldman C. The use of corticosteroids for COVID-19 infection. Afr J Thorac Crit Care Med 2020;26. [PMID: 34235424 DOI: 10.7196/AJTCCM.2020.v26i3.106] [Reference Citation Analysis]
177 Gelfand JM, Armstrong AW, Bell S, Anesi GL, Blauvelt A, Calabrese C, Dommasch ED, Feldman SR, Gladman D, Kircik L, Lebwohl M, Lo Re V 3rd, Martin G, Merola JF, Scher JU, Schwartzman S, Treat JR, Van Voorhees AS, Ellebrecht CT, Fenner J, Ocon A, Syed MN, Weinstein EJ, Smith J, Gondo G, Heydon S, Koons S, Ritchlin CT. National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. J Am Acad Dermatol. 2020;83:1704-1716. [PMID: 32891785 DOI: 10.1016/j.jaad.2020.09.001] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
178 Lee JW, Song EM, Jung SA, Jung SH, Kim KW, Koh SJ, Lee HJ, Hong SW, Park JH, Hwang SW, Yang DH, Ye BD, Byeon JS, Myung SJ, Yang SK, Park SH; IBD Research Group of the Korean Association for the Study of Intestinal Diseases. Clinical Course of COVID-19 in Patients with Inflammatory Bowel Disease in Korea: a KASID Multicenter Study. J Korean Med Sci 2021;36:e336. [PMID: 34904410 DOI: 10.3346/jkms.2021.36.e336] [Reference Citation Analysis]
179 Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, Richter J, Schäfer M, Schmeiser T, Strangfeld A, Schulze-Koops H, Voll RE, Specker C, Regierer AC. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open 2021;7:e001464. [PMID: 33479021 DOI: 10.1136/rmdopen-2020-001464] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
180 Koletzko L, Klucker E, Le Thi TG, Breiteneicher S, Rubio-Acero R, Neuhaus L, Stark RG, Standl M, Wieser A, Török H, Koletzko S, Schwerd T. Following Pediatric and Adult IBD Patients through the COVID-19 Pandemic: Changes in Psychosocial Burden and Perception of Infection Risk and Harm over Time. J Clin Med 2021;10:4124. [PMID: 34575235 DOI: 10.3390/jcm10184124] [Reference Citation Analysis]
181 Harrison N, Humes R, Singla M. Skip, Stop, Switch, and Spare: Steroid Therapy in Inflammatory Bowel Disease. Am J Gastroenterol 2021;116:1819-21. [PMID: 34279011 DOI: 10.14309/ajg.0000000000001380] [Reference Citation Analysis]
182 Robinson PC, Morand E. Divergent effects of acute versus chronic glucocorticoids in COVID-19. Lancet Rheumatol 2021;3:e168-70. [PMID: 33521656 DOI: 10.1016/S2665-9913(21)00005-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
183 Popa IV, Diculescu M, Mihai C, Cijevschi-Prelipcean C, Burlacu A. COVID-19 and Inflammatory Bowel Diseases: Risk Assessment, Shared Molecular Pathways, and Therapeutic Challenges. Gastroenterol Res Pract 2020;2020:1918035. [PMID: 32714386 DOI: 10.1155/2020/1918035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
184 Kishk A, Pacheco MP, Sauter T. DCcov: Repositioning of drugs and drug combinations for SARS-CoV-2 infected lung through constraint-based modeling. iScience 2021;24:103331. [PMID: 34723158 DOI: 10.1016/j.isci.2021.103331] [Reference Citation Analysis]
185 Bouffard MA, Levy M, Lee AG, Van Stavern GP. Should Immunosuppressive Therapy Be Modified During a Pandemic? J Neuroophthalmol 2021;41:266-71. [PMID: 33999890 DOI: 10.1097/WNO.0000000000001274] [Reference Citation Analysis]
186 Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, Mateus EF, Richez C, Santos MJ, Schmajuk G, Scirè CA, Sirotich E, Sparks JA, Sufka P, Thomas T, Trupin L, Wallace ZS, Al-Adely S, Bachiller-Corral J, Bhana S, Cacoub P, Carmona L, Costello R, Costello W, Gossec L, Grainger R, Hachulla E, Hasseli R, Hausmann JS, Hyrich KL, Izadi Z, Jacobsohn L, Katz P, Kearsley-Fleet L, Robinson PC, Yazdany J, Machado PM; COVID-19 Global Rheumatology Alliance. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis 2021;80:930-42. [PMID: 33504483 DOI: 10.1136/annrheumdis-2020-219498] [Cited by in Crossref: 89] [Cited by in F6Publishing: 89] [Article Influence: 89.0] [Reference Citation Analysis]
187 Ward D, Gørtz S, Ernst MT, Andersen NN, Kjær SK, Hallas J, Christensen S, Christiansen CF, Israelsen SB, Benfield T, Pottegård A, Jess T. The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection. Eur Respir J 2021:2100769. [PMID: 34475227 DOI: 10.1183/13993003.00769-2021] [Reference Citation Analysis]
188 Gajendran M, Perisetti A, Aziz M, Raghavapuram S, Bansal P, Tharian B, Goyal H. Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned. Ann Gastroenterol. 2020;33:591-602. [PMID: 33162736 DOI: 10.20524/aog.2020.0547] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
189 Attauabi M, Poulsen A, Theede K, Pedersen N, Larsen L, Jess T, Rosager Hansen M, Verner-Andersen MK, V Haderslev K, Berg Lødrup A, Molazahi A, Neumann A, Wase A, Seidelin JB, Burisch J. Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease-A Danish Prospective Population-based Cohort Study.J Crohns Colitis. 2021;15:540-550. [PMID: 33035299 DOI: 10.1093/ecco-jcc/jjaa205] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
190 D'Silva KM, Wallace ZS. COVID-19 and Disease-Modifying Anti-rheumatic Drugs. Curr Rheumatol Rep 2021;23:28. [PMID: 33893890 DOI: 10.1007/s11926-021-00998-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
191 Lafaurie M, Martin-Blondel G, Delobel P, Kamar N, Charpentier S, Sommet A, Moulis G; Covid-Clinic-Toul investigators. Impact of previous exposure to systemic corticosteroids on unfavorable outcome in patients hospitalized for COVID-19. BMC Pharmacol Toxicol 2021;22:14. [PMID: 33706794 DOI: 10.1186/s40360-021-00480-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
192 Brenner EJ, Ungaro RC, Colombel JF, Kappelman MD. IBD in the COVID-19 era: the value of international collaboration. Lancet Gastroenterol Hepatol 2020;5:887-8. [PMID: 32941833 DOI: 10.1016/S2468-1253(20)30269-7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
193 Winthrop KL, Mariette X. To immunosuppress: whom, when and how? That is the question with COVID-19. Ann Rheum Dis 2020;79:1129-31. [PMID: 32753413 DOI: 10.1136/annrheumdis-2020-218694] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
194 Taxonera C, Alba C. Letter: SARS-CoV-2 induced gastrointestinal inflammation-authors' reply. Aliment Pharmacol Ther 2020;52:1750-1. [PMID: 33205880 DOI: 10.1111/apt.16117] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
195 Kjeldsen S, Nielsen J, Mertz Nørgård B, Kjeldsen J. Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data. Inflamm Bowel Dis 2021:izab299. [PMID: 34849917 DOI: 10.1093/ibd/izab299] [Reference Citation Analysis]
196 Targownik LE, Bernstein CN, Benchimol EI, Kaplan GG, Singh H, Tennakoon A, Nugent Z, Coward SB, Kuenzig ME, Murthy SK. Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis. Am J Gastroenterol 2021;116:1284-93. [PMID: 33767103 DOI: 10.14309/ajg.0000000000001220] [Reference Citation Analysis]
197 Ruan W, Nguyen H, Wyatt A, Ihekweazu F, Vartabedian BS, Karam L, Walsh S, Kellermayer R. High Seroconversion Rate Against Severe Acute Respiratory Syndrome Coronavirus 2 in Symptomatic Pediatric Inflammatory Bowel Disease Patients. J Pediatr Gastroenterol Nutr 2021;73:363-6. [PMID: 34173793 DOI: 10.1097/MPG.0000000000003211] [Reference Citation Analysis]
198 Eviatar T, Elalouf O, Furer V, Goldstein-Lahat Y, Paran Y, Pel S, Nevo S, Zisapel M, Alcalay Y, Elkayam O. Prevalence of COVID-19 and seroprevalence to SARS-CoV-2 in a rheumatologic patient population from a tertiary referral clinic in Israel. Intern Med J 2021;51:682-90. [PMID: 33844415 DOI: 10.1111/imj.15202] [Reference Citation Analysis]
199 [DOI: 10.1101/2020.09.07.20189621] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
200 Wong GL, Yip TC, Wong VW, Tse YK, Hui DS, Lee SS, Yeoh EK, Chan HL, Lui GC. SARS-CoV-2 Viral Persistence Based on Cycle Threshold Value and Liver Injury in Patients With COVID-19. Open Forum Infect Dis 2021;8:ofab205. [PMID: 34099979 DOI: 10.1093/ofid/ofab205] [Reference Citation Analysis]
201 Norsa L, Cosimo P, Indriolo A, Sansotta N, D'Antiga L, Callegaro A. Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Patients With Inflammatory Bowel Disease Under Biologic Treatment.Gastroenterology. 2020;159:2229-2231.e2. [PMID: 32860790 DOI: 10.1053/j.gastro.2020.08.046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
202 Liao SY, Petrache I, Fingerlin TE, Maier LA. Association of inhaled and systemic corticosteroid use with Coronavirus Disease 2019 (COVID-19) test positivity in patients with chronic pulmonary diseases. Respir Med 2021;176:106275. [PMID: 33276252 DOI: 10.1016/j.rmed.2020.106275] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
203 Umnuaypornlert A, Kanchanasurakit S, Lucero-Prisno DEI, Saokaew S. Smoking and risk of negative outcomes among COVID-19 patients: A systematic review and meta-analysis.Tob Induc Dis. 2021;19:09. [PMID: 33551713 DOI: 10.18332/tid/132411] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
204 Pinte L, Caraiola S, Balaban DV, Badea C, Mazilu D, Ionescu GD, Iosub MI, Bălan ES, Negoi F, Dumitrescu B, Mateescu B, Ionescu R, Parvu MI, Baicus C. COVID-19 Impact and Vaccination Willingness among Romanian Patients with Autoimmune/Immune-Mediated Diseases. Healthcare (Basel) 2021;9:1707. [PMID: 34946433 DOI: 10.3390/healthcare9121707] [Reference Citation Analysis]
205 Windsor JW, Underwood FE, Brenner E, Colombel J, Kappelman MD, Ungaro R, Zhang X, Kaplan GG. Data Visualization in the Era of COVID-19: An Interactive Map of the SECURE-IBD Registry. Am J Gastroenterol 2020;115:1923-4. [DOI: 10.14309/ajg.0000000000000953] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
206 Izadi Z, Brenner EJ, Mahil SK, Dand N, Yiu ZZN, Yates M, Ungaro RC, Zhang X, Agrawal M, Colombel JF, Gianfrancesco MA, Hyrich KL, Strangfeld A, Carmona L, Mateus EF, Lawson-Tovey S, Klingberg E, Cuomo G, Caprioli M, Cruz-Machado AR, Mazeda Pereira AC, Hasseli R, Pfeil A, Lorenz HM, Hoyer BF, Trupin L, Rush S, Katz P, Schmajuk G, Jacobsohn L, Seet AM, Al Emadi S, Wise L, Gilbert EL, Duarte-García A, Valenzuela-Almada MO, Isnardi CA, Quintana R, Soriano ER, Hsu TY, D'Silva KM, Sparks JA, Patel NJ, Xavier RM, Marques CDL, Kakehasi AM, Flipo RM, Claudepierre P, Cantagrel A, Goupille P, Wallace ZS, Bhana S, Costello W, Grainger R, Hausmann JS, Liew JW, Sirotich E, Sufka P, Robinson PC, Machado PM, Griffiths CEM, Barker JN, Smith CH, Yazdany J, Kappelman MD; Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Allianc., Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection (PsoProtect); the Secure Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease (SECURE-IBD); and the COVID-19 Global Rheumatology Alliance (GRA). Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Netw Open 2021;4:e2129639. [PMID: 34661663 DOI: 10.1001/jamanetworkopen.2021.29639] [Reference Citation Analysis]
207 Reinisch W, Danese S, Peyrin-Biroulet L, Loftus EV. Clinical Trials for Inflammatory Bowel Disease: Global Guidance During the COVID-19 Pandemic. J Crohns Colitis 2020;14:S815-9. [PMID: 32520311 DOI: 10.1093/ecco-jcc/jjaa119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
208 Spadaccini M, Canziani L, Aghemo A, Lleo A, Maselli R, Anderloni A, Carrara S, Fugazza A, Pellegatta G, Galtieri PA, Hassan C, Greenwald D, Pochapin M, Wallace M, Sharma P, Roesch T, Bhandari P, Emura F, Raju GS, Repici A. What gastroenterologists should know about SARS-CoV 2 vaccine: World Endoscopy Organization perspective. United European Gastroenterol J 2021. [PMID: 34102015 DOI: 10.1002/ueg2.12103] [Reference Citation Analysis]
209 Wong SY, Dixon R, Martinez Pazos V, Gnjatic S, Colombel JF, Cadwell K; ICARUS-IBD Working Group. Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. Gastroenterology 2021;161:715-718.e4. [PMID: 33887219 DOI: 10.1053/j.gastro.2021.04.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
210 Nowak JK, Kalla R, Satsangi J. Reply. Gastroenterology 2021;160:2622-3. [PMID: 33549534 DOI: 10.1053/j.gastro.2021.02.011] [Reference Citation Analysis]
211 Rodríguez-Lago I, Alonso-Galán H, Cabriada JL. Cytokine Storm in IBD: Balancing the Risks of IBD Medical Therapy. Gastroenterology 2021;160:1878-80. [PMID: 33417936 DOI: 10.1053/j.gastro.2020.12.073] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
212 Khan N, Patel D, Xie D, Lewis J, Trivedi C, Yang YX. Impact of Anti-Tumor Necrosis Factor and Thiopurine Medications on the Development of COVID-19 in Patients With Inflammatory Bowel Disease: A Nationwide Veterans Administration Cohort Study. Gastroenterology 2020;159:1545-1546.e1. [PMID: 32479823 DOI: 10.1053/j.gastro.2020.05.065] [Cited by in Crossref: 16] [Cited by in F6Publishing: 26] [Article Influence: 8.0] [Reference Citation Analysis]
213 Sarfaty M, Feldman DR, Morris MJ, Motzer RJ, Rathkopf DE, Regazzi AM, Iyer G, Voss MH, Bajorin DF, Rosenberg JE. Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. Clin Genitourin Cancer 2021;19:e178-83. [PMID: 33579638 DOI: 10.1016/j.clgc.2020.12.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
214 Scaldaferri F, Ianiro G, Privitera G, Lopetuso LR, Vetrone LM, Petito V, Pugliese D, Neri M, Cammarota G, Ringel Y, Costamagna G, Gasbarrini A, Boskoski I, Armuzzi A. The Thrilling Journey of SARS-CoV-2 into the Intestine: From Pathogenesis to Future Clinical Implications. Inflamm Bowel Dis. 2020;26:1306-1314. [PMID: 32720978 DOI: 10.1093/ibd/izaa181] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
215 Ardizzone S, Ferretti F, Monico MC, Carvalhas Gabrielli AM, Carmagnola S, Bezzio C, Saibeni S, Bosani M, Caprioli F, Mazza S, Casini V, Cortelezzi CC, Parravicini M, Cassinotti A, Cosimo P, Indriolo A, Di Sabatino A, Lenti MV, Pastorelli L, Conforti F, Ricci C, Sarzi-Puttini P, Vecchi M, Maconi G. Lower incidence of COVID-19 in patients with inflammatory bowel disease treated with non-gut selective biologic therapy. J Gastroenterol Hepatol 2021. [PMID: 34159648 DOI: 10.1111/jgh.15591] [Reference Citation Analysis]
216 Calvet X, Carpio D, Rodríguez-Lago I, García-Vicuña R, Barreiro-de-Acosta M, Juanola X, Aguas M, Castillo C, Gratacós J. Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies. Gastroenterol Hepatol 2021:S0210-5705(21)00056-X. [PMID: 33640469 DOI: 10.1016/j.gastrohep.2021.01.007] [Reference Citation Analysis]
217 Lukin DJ, Funez-dePagnier G, Lima S, Lai D, Duenas-Bianchi L, Ahmed W, Jacob V, Battat R, Scherl E, Longman RS. No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD. Clin Gastroenterol Hepatol 2021;19:2312-2314.e3. [PMID: 34102340 DOI: 10.1016/j.cgh.2021.06.008] [Reference Citation Analysis]
218 Vodnar DC, Mitrea L, Teleky BE, Szabo K, Călinoiu LF, Nemeş SA, Martău GA. Coronavirus Disease (COVID-19) Caused by (SARS-CoV-2) Infections: A Real Challenge for Human Gut Microbiota. Front Cell Infect Microbiol 2020;10:575559. [PMID: 33363049 DOI: 10.3389/fcimb.2020.575559] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
219 Dimopoulos C, Al-Bawardy B. SARS-CoV-2 Infection and Dual-Biologic Therapy for Crohn's Disease. Inflamm Bowel Dis 2020;26:e153-4. [PMID: 33043966 DOI: 10.1093/ibd/izaa275] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
220 Beattie RM, Ashton JJ, Penman ID. COVID-19 and the gastrointestinal tract: recent data. Frontline Gastroenterol. 2020;11:371-374. [PMID: 32879720 DOI: 10.1136/flgastro-2020-101602] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
221 Zhang J, Garrett S, Sun J. Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19. Genes Dis 2021;8:385-400. [PMID: 33521210 DOI: 10.1016/j.gendis.2020.08.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
222 Montero F, Martínez-Barrio J, Serrano-Benavente B, González T, Rivera J, Molina Collada J, Castrejón I, Álvaro-Gracia J. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int 2020;40:1593-8. [PMID: 32794113 DOI: 10.1007/s00296-020-04676-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
223 Calabrese C, Lehman B. COVID-19: a primer for the rheumatologist: management of patients and care settings. Curr Opin Rheumatol 2020;32:429-33. [PMID: 32744823 DOI: 10.1097/BOR.0000000000000732] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
224 Parekh R, Zhang X, Ungaro RC, Brenner EJ, Agrawal M, Colombel JF, Kappelman MD. Presence of Comorbidities Associated with Severe Coronavirus Infection in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2021. [PMID: 34181165 DOI: 10.1007/s10620-021-07104-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
225 Connelly JA, Chong H, Esbenshade AJ, Frame D, Failing C, Secord E, Walkovich K. Impact of COVID-19 on Pediatric Immunocompromised Patients. Pediatr Clin North Am 2021;68:1029-54. [PMID: 34538297 DOI: 10.1016/j.pcl.2021.05.007] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
226 Suzaki I, Kobayashi H. Coronavirus Disease 2019 and Nasal Conditions: A Review of Current Evidence. In Vivo 2021;35:1409-17. [PMID: 33910818 DOI: 10.21873/invivo.12393] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
227 Tsankov BK, Allaire JM, Irvine MA, Lopez AA, Sauvé LJ, Vallance BA, Jacobson K. Severe COVID-19 Infection and Pediatric Comorbidities: A Systematic Review and Meta-Analysis. Int J Infect Dis 2021;103:246-56. [PMID: 33227520 DOI: 10.1016/j.ijid.2020.11.163] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
228 Magro F, Dias CC, Morato M. Aminosalicylates and COVID-19: Facts or Coincidences? Gastroenterology 2021;160:1884-5. [PMID: 32553757 DOI: 10.1053/j.gastro.2020.05.092] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
229 Jing R, Vunnam RR, Schnaubelt E, Vokoun C, Cushman-Vokoun A, Goldner D, Vunnam SR. Co-infection of COVID-19 and influenza A in a hemodialysis patient: a case report. BMC Infect Dis 2021;21:68. [PMID: 33441085 DOI: 10.1186/s12879-020-05723-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
230 Dipasquale V, Passanisi S, Cucinotta U, Cascio A, Romano C. Implications of SARS-COV-2 infection in the diagnosis and management of the pediatric gastrointestinal disease. Ital J Pediatr 2021;47:71. [PMID: 33761992 DOI: 10.1186/s13052-021-01020-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Cappello M, Busacca A, Guida L. The Course of COVID-19 in Inflammatory Bowel Disease: Protective Role of TNF Antagonists. Gastroenterology 2021;160:1885-6. [PMID: 32645320 DOI: 10.1053/j.gastro.2020.06.087] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
232 Wu X, Lin J, Buch H, Ding Q, Zhang F, Cui B, Ji G. The COVID-19 Vaccination Hesitancy Among the People With Inflammatory Bowel Disease in China: A Questionnaire Study. Front Public Health 2021;9:731578. [PMID: 34708016 DOI: 10.3389/fpubh.2021.731578] [Reference Citation Analysis]
233 Hertanto DM, Wiratama BS, Sutanto H, Wungu CDK. Immunomodulation as a Potent COVID-19 Pharmacotherapy: Past, Present and Future. J Inflamm Res 2021;14:3419-28. [PMID: 34321903 DOI: 10.2147/JIR.S322831] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
234 D'Amico F, Danese S, Peyrin-Biroulet L. Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock. Clin Gastroenterol Hepatol. 2020;18:2689-2700. [PMID: 32777550 DOI: 10.1016/j.cgh.2020.08.003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 9.5] [Reference Citation Analysis]
235 Sparks JA, Wallace ZS, Robinson PC. Coronavirus disease 2019: update on coronavirus disease 2019 outcomes and vaccine efficacy in patients with immune-mediated inflammatory disease. Curr Opin Rheumatol 2021;33:412-8. [PMID: 34171857 DOI: 10.1097/BOR.0000000000000812] [Reference Citation Analysis]
236 Rozet F, Mongiat-Artus P, Ploussard G, Rouprêt M, Cacoub P, Fournier G, Mathieu R. [Update on the risk of corticosterone therapy in combination with abiraterone acetate during the COVID-19 pandemic]. Prog Urol 2021;31:243-4. [PMID: 33468416 DOI: 10.1016/j.purol.2020.12.002] [Reference Citation Analysis]
237 Alegiani SS, Crisafulli S, Rossi PG, Mancuso P, Salvarani C, Atzeni F, Gini R, Kirchmayer U, Belleudi V, Kurotschka PK, Leoni O, Ludergnani M, Ferroni E, Baracco S, Massari M, Trifirò G; ITA-COVID-19 Network. Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy. Rheumatology (Oxford) 2021:keab348. [PMID: 33856453 DOI: 10.1093/rheumatology/keab348] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
238 Tominaga K, Sugaya T, Tanaka T, Kanazawa M, Iijima M, Irisawa A. Thiopurines: Recent Topics and Their Role in the Treatment of Inflammatory Bowel Diseases. Front Pharmacol 2020;11:582291. [PMID: 33584261 DOI: 10.3389/fphar.2020.582291] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
239 Roy K, Agarwal S, Banerjee R, Paul MK, Purbey PK. COVID-19 and gut immunomodulation. World J Gastroenterol 2021; 27(46): 7925-7942 [DOI: 10.3748/wjg.v27.i46.7925] [Reference Citation Analysis]
240 Noor NM, Hart AL, Irving PM, Ghosh S, Parkes M, Raine T. Clinical trials (and tribulations): the immediate effects of COVID-19 on IBD clinical research activity in the United Kingdom. J Crohns Colitis 2020:jjaa137. [PMID: 32598438 DOI: 10.1093/ecco-jcc/jjaa137] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
241 Bossa F, Carparelli S, Latiano A, Palmieri O, Tavano F, Panza A, Pastore M, Marseglia A, D'Altilia M, Latiano T, Corritore G, Martino G, Nardella M, Guerra M, Terracciano F, Sacco M, Perri F, Andriulli A. Impact of the COVID-19 outbreak and the serum prevalence of SARS-CoV-2 antibodies in patients with inflammatory bowel disease treated with biologic drugs. Dig Liver Dis. 2021;53:277-282. [PMID: 33423942 DOI: 10.1016/j.dld.2020.12.120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
242 Caffo O, Messina M, Veccia A, Kinspergher S, Maines F, Messina C. Severe acute respiratory syndrome coronavirus 2 infection in patients with prostate cancer: A critical review. Crit Rev Oncol Hematol 2021;167:103491. [PMID: 34626792 DOI: 10.1016/j.critrevonc.2021.103491] [Reference Citation Analysis]
243 Wetwittayakhlang P, Albader F, Golovics PA, Hahn GD, Bessissow T, Bitton A, Afif W, Wild G, Lakatos PL. Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease. Can J Gastroenterol Hepatol 2021;2021:7591141. [PMID: 34858891 DOI: 10.1155/2021/7591141] [Reference Citation Analysis]
244 Lei HY, Ding YH, Nie K, Dong YM, Xu JH, Yang ML, Liu MQ, Wei L, Nasser MI, Xu LY, Zhu P, Zhao MY. Potential effects of SARS-CoV-2 on the gastrointestinal tract and liver. Biomed Pharmacother 2021;133:111064. [PMID: 33378966 DOI: 10.1016/j.biopha.2020.111064] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
245 Magro F, Nuzzo A, Abreu C, Libânio D, Rodriguez-Lago I, Pawlak K, Hollenbach M, Brouwer WP, Siau K. COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology. United European Gastroenterol J 2021. [PMID: 34190413 DOI: 10.1002/ueg2.12115] [Reference Citation Analysis]
246 Pearson MM, Limaye AP, Biggins SW. Tacrolimus: Unlikely Harmful and Perhaps Helpful in Liver Transplant Recipients with COVID-19. Gastroenterology. 2021;160:1012-1013. [PMID: 33387518 DOI: 10.1053/j.gastro.2020.12.050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
247 Nissen CB, Sciascia S, de Andrade D, Atsumi T, Bruce IN, Cron RQ, Hendricks O, Roccatello D, Stach K, Trunfio M, Vinet É, Schreiber K. The role of antirheumatics in patients with COVID-19. Lancet Rheumatol 2021;3:e447-59. [PMID: 33817665 DOI: 10.1016/S2665-9913(21)00062-X] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
248 Kang JH, Bluestone JA, Young A. Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines. Trends Immunol 2021;42:293-311. [PMID: 33714688 DOI: 10.1016/j.it.2021.02.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
249 Ku CR, Jung KY, Ahn CH, Moon JS, Lee JH, Kim EH, Kwon H, Kim HK, Suh S, Hong S, Ha J, Roh E, Kim JH, Kim MK; Committee of Clinical Practice Guideline of the Korean Endocrine Society. COVID-19 Vaccination for Endocrine Patients: A Position Statement from the Korean Endocrine Society. Endocrinol Metab (Seoul) 2021;36:757-65. [PMID: 34399446 DOI: 10.3803/EnM.2021.404] [Reference Citation Analysis]
250 Saleh A, Sultan A, Elashry MA, Farag A, Mortada MI, Ghannam MA, Saed AM, Ghoneem S. Association of TNF-α G-308 a Promoter Polymorphism with the Course and Outcome of COVID-19 Patients. Immunol Invest 2020;:1-12. [PMID: 33228423 DOI: 10.1080/08820139.2020.1851709] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
251 Alrashed F, Battat R, Abdullah I, Charabaty A, Shehab M. Impact of medical therapies for inflammatory bowel disease on the severity of COVID-19: a systematic review and meta-analysis. BMJ Open Gastroenterol 2021;8:e000774. [PMID: 34725056 DOI: 10.1136/bmjgast-2021-000774] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
252 Ricciotti E, Laudanski K, FitzGerald GA. Nonsteroidal anti-inflammatory drugs and glucocorticoids in COVID-19. Adv Biol Regul 2021;81:100818. [PMID: 34303107 DOI: 10.1016/j.jbior.2021.100818] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
253 Leibel SL, Sun X. COVID-19 in Early Life: Infants and Children Are Affected Too. Physiology (Bethesda) 2021;36:359-66. [PMID: 34704855 DOI: 10.1152/physiol.00022.2021] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
254 Gallo CG, Fiorino S, Posabella G, Antonacci D, Tropeano A, Pausini E, Pausini C, Guarniero T, Hong W, Giampieri E, Corazza I, Federico L, de Biase D, Zippi M, Zancanaro M. COVID-19, what could sepsis, severe acute pancreatitis, gender differences, and aging teach us? Cytokine 2021;148:155628. [PMID: 34411989 DOI: 10.1016/j.cyto.2021.155628] [Reference Citation Analysis]
255 Melmed GY, Rubin DT, McGovern DPB. Winter Is Coming! Clinical, Immunologic, and Practical Considerations for Vaccinating Patients With Inflammatory Bowel Disease During the Coronavirus Disease-2019 Pandemic. Gastroenterology 2021;160:639-44. [PMID: 33065064 DOI: 10.1053/j.gastro.2020.10.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
256 Kaplan GG, Windsor JW, Crain J, Barrett L, Bernstein CN, Bitton A, Chauhan U, Coward S, Fowler S, Ghia JE, Gibson DL, Griffiths AM, Jones JL, Khanna R, Kuenzig ME, Lakatos PL, Lee K, Mack DR, Marshall JK, Mawani M, Murthy SK, Panaccione R, Seow CH, Targownik LE, Zelinsky S, Benchimol EI. Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy. J Can Assoc Gastroenterol 2021;4:S10-9. [PMID: 34755034 DOI: 10.1093/jcag/gwab028] [Reference Citation Analysis]
257 Ayala Gutiérrez MDM, Rubio-Rivas M, Romero Gómez C, Montero Sáez A, Pérez de Pedro I, Homs N, Ayuso García B, Cuenca Carvajal C, Arnalich Fernández F, Beato Pérez JL, Vargas Núñez JA, Letona Giménez L, Suárez Fernández C, Méndez Bailón M, Tuñón de Almeida C, González Moraleja J, de Guzmán García-Monge M, Helguera Amezua C, Fidalgo Montero MDP, Giner Galvañ V, Gil Sánchez R, Collado Sáenz J, Boixeda R, Ramos Rincón JM, Gómez Huelgas R, On Behalf Of The Semi-Covid-Network. Autoimmune Diseases and COVID-19 as Risk Factors for Poor Outcomes: Data on 13,940 Hospitalized Patients from the Spanish Nationwide SEMI-COVID-19 Registry. J Clin Med 2021;10:1844. [PMID: 33922777 DOI: 10.3390/jcm10091844] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
258 Mir N, Cheesbrough J, Troth T, Hussain N, Hopkins LJ, Shi J, Sarker N, Smith E, Courtney F, Flaherty J, Hill R, Jebb S, Kakosa V, Calderwood J, Sharma N, McCulloch A, Quraishi MN. COVID-19-related health anxieties and impact of specific interventions in patients with inflammatory bowel disease in the UK. Frontline Gastroenterol 2021;12:200-6. [PMID: 33903816 DOI: 10.1136/flgastro-2020-101633] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
259 Viganò C, Mulinacci G, Palermo A, Barisani D, Pirola L, Fichera M, Invernizzi P, Massironi S. Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future. World J Gastroenterol 2021; 27(33): 5520-5535 [PMID: 34588749 DOI: 10.3748/wjg.v27.i33.5520] [Reference Citation Analysis]
260 Arrigo S, Alvisi P, Banzato C, Bramuzzo M, Civitelli F, Corsello A, D'Arcangelo G, Dilillo A, Dipasquale V, Felici E, Fuoti M, Gatti S, Giusti Z, Knafelz D, Lionetti P, Mario F, Marseglia A, Martelossi S, Moretti C, Norsa L, Nuti F, Panceri R, Rampado S, Renzo S, Romano C, Romeo E, Strisciuglio C, Martinelli M. Management of paediatric IBD after the peak of COVID-19 pandemic in Italy: A position paper on behalf of the SIGENP IBD working group. Dig Liver Dis. 2021;53:183-189. [PMID: 33132063 DOI: 10.1016/j.dld.2020.10.024] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
261 Ungaro RC, Brenner EJ, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, Ng SC, Rahier JF, Reinisch W, Steinwurz F, Underwood FE, Zhang X, Colombel JF, Kappelman MD. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut 2021;70:725-32. [PMID: 33082265 DOI: 10.1136/gutjnl-2020-322539] [Cited by in Crossref: 59] [Cited by in F6Publishing: 76] [Article Influence: 29.5] [Reference Citation Analysis]
262 Dailey J, Kozhaya L, Dogan M, Hopkins D, Lapin B, Herbst K, Brimacombe M, Grandonico K, Karabacak F, Schreiber J, Liang BT, Salazar JC, Unutmaz D, Hyams JS. Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab207. [PMID: 34528661 DOI: 10.1093/ibd/izab207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
263 Pablos JL, Galindo M, Carmona L, Lledó A, Retuerto M, Blanco R, Gonzalez-Gay MA, Martinez-Lopez D, Castrejón I, Alvaro-Gracia JM, Fernández Fernández D, Mera-Varela A, Manrique-Arija S, Mena Vázquez N, Fernandez-Nebro A; RIER Investigators Group., RIER investigators group. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. Ann Rheum Dis 2020;79:1544-9. [PMID: 32796045 DOI: 10.1136/annrheumdis-2020-218296] [Cited by in Crossref: 47] [Cited by in F6Publishing: 46] [Article Influence: 23.5] [Reference Citation Analysis]
264 Marques CDL; ReumaCoV Brasil Study Group. COVID-19 and Rheumatic Diseases: It Is Time to Better Understand This Association. J Rheumatol 2021;48:318-20. [PMID: 34237001 DOI: 10.3899/jrheum.201541] [Reference Citation Analysis]
265 Khan N, Mahmud N, Trivedi C, Reinisch W, Lewis JD. Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System. Gut 2021;70:1657-64. [PMID: 33753416 DOI: 10.1136/gutjnl-2021-324356] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
266 Patel S, Wadhwa M. Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19. Biomed Pharmacother 2021;140:111785. [PMID: 34126316 DOI: 10.1016/j.biopha.2021.111785] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
267 Brain O, Satsangi J. Therapeutic Decisions in Inflammatory Bowel Disease in the SARS-Cov-2 Pandemic. Gastroenterology 2021;160:1883-4. [PMID: 32553759 DOI: 10.1053/j.gastro.2020.05.083] [Reference Citation Analysis]
268 Hausmann JS, Sufka P, Bhana S, Liew JW, Machado PM, Wallace ZS, Costello W, Robinson PC, Yazdany J, Grainger R, Sirotich E. Conducting research in a pandemic: The power of social media. Eur J Rheumatol 2020;7:S85-8. [PMID: 32716838 DOI: 10.5152/eurjrheum.2020.2066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
269 Norsa L, D'Antiga L. Reply. Gastroenterology 2021;160:474-5. [PMID: 33159926 DOI: 10.1053/j.gastro.2020.11.001] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
270 Grainger R, Machado PM, Robinson PC. Novel coronavirus disease-2019 (COVID-19) in people with rheumatic disease: Epidemiology and outcomes. Best Pract Res Clin Rheumatol 2021;35:101657. [PMID: 33468418 DOI: 10.1016/j.berh.2020.101657] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
271 Sweed D, Abdelsameea E, Khalifa EA, Abdallah H, Moaz H, Moaz I, Abdelsattar S, Abdel-Rahman N, Mosbeh A, Elmahdy HA, Sweed E. SARS-CoV-2-associated gastrointestinal and liver diseases: what is known and what is needed to explore. Egypt Liver J 2021;11:64. [PMID: 34777871 DOI: 10.1186/s43066-021-00123-6] [Reference Citation Analysis]
272 Taxonera C, Sagastagoitia I, Alba C, Mañas N, Olivares D, Rey E. Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2-exploring RAS inhibitors. Authors' reply. Aliment Pharmacol Ther 2020;52:571-2. [PMID: 32583443 DOI: 10.1111/apt.15893] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
273 Kondle S, Hou T, Manansala M, Ascoli C, Novak RM, Sweiss N. Treatment of COVID-19 in Patients With Sarcoidosis. Front Med (Lausanne) 2021;8:689539. [PMID: 34336892 DOI: 10.3389/fmed.2021.689539] [Reference Citation Analysis]
274 Rieker L, Hofer J, Petzold G, Ellenrieder V, Amanzada A. Induction of remission with tacrolimus in a patient with severe acute, cortisone refractory ulcerative colitis and severe Covid-19 pneumonia: a case report. BMC Gastroenterol 2022;22:22. [PMID: 35033015 DOI: 10.1186/s12876-022-02094-3] [Reference Citation Analysis]
275 Bardasi G, Alvisi P. SARS-CoV-2 infection in severe pediatric Crohn's disease. What about anti-tumor necrosis factor α therapy? Dig Liver Dis 2020;52:1244-5. [PMID: 32703727 DOI: 10.1016/j.dld.2020.06.047] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
276 Kakimoto K, Matsuura M, Fukuchi T, Hongo H, Kimura T, Aoyama N, Okuda Y, Aomatsu K, Kamata N, Yokoyama Y, Mizuno C, Inoue T, Miyazaki T, Nakamura S, Higuchi K, Nakase H. Exploratory Study of the Effectiveness of Granulocyte and Monocyte Adsorptive Apheresis Before Initiation of Steroids in Patients With Active Ulcerative Colitis (EXPECT Study): A Multicenter Prospective Clinical Trial. Crohns Colitis 360 2020;2:otaa073. [PMID: 34192247 DOI: 10.1093/crocol/otaa073] [Reference Citation Analysis]
277 Alcock J, Masters A. Cytokine storms, evolution and COVID-19. Evol Med Public Health 2021;9:83-92. [PMID: 34552755 DOI: 10.1093/emph/eoab005] [Reference Citation Analysis]
278 Akiyama S, Hamdeh S, Micic D, Sakuraba A. Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis. Ann Rheum Dis 2020:annrheumdis-2020-218946. [PMID: 33051220 DOI: 10.1136/annrheumdis-2020-218946] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 25.0] [Reference Citation Analysis]
279 Ghazawi FM, Lim M, Dutz JP, Kirchhof MG. Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration. Int J Dermatol 2020;59:1043-56. [PMID: 32621284 DOI: 10.1111/ijd.15028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
280 Robinson PC, Liew DFL, Liew JW, Monaco C, Richards D, Shivakumar S, Tanner HL, Feldmann M. The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. Med (N Y) 2020;1:90-102. [PMID: 33294881 DOI: 10.1016/j.medj.2020.11.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 8.0] [Reference Citation Analysis]
281 Kridin K, Schonmann Y, Solomon A, Damiani G, Tzur Bitan D, Onn E, Weinstein O, Cohen AD. Risk of COVID-19 Infection, Hospitalization, and Mortality in Patients with Psoriasis Treated by Interleukin-17 Inhibitors. J Dermatolog Treat 2021;:1-28. [PMID: 33759683 DOI: 10.1080/09546634.2021.1905766] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
282 Macaluso FS, Orlando A. COVID-19 in patients with inflammatory bowel disease: A systematic review of clinical data. Dig Liver Dis 2020;52:1222-7. [PMID: 32928672 DOI: 10.1016/j.dld.2020.09.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
283 Dalal RS, McClure E, Marcus J, Winter RW, Hamilton MJ, Allegretti JR. COVID-19 Vaccination Intent and Perceptions Among Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2021;19:1730-1732.e2. [PMID: 33549869 DOI: 10.1016/j.cgh.2021.02.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 15.0] [Reference Citation Analysis]
284 Mao R, Rieder F, Ben-Horin S, Kaplan GG, Ng SC, Wong GL, Ghosh S, Chen MH. Implications of COVID-19 for patients with pre-existing digestive diseases: an update. Lancet Gastroenterol Hepatol. 2021;6:258-260. [PMID: 33539813 DOI: 10.1016/s2468-1253(21)00025-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
285 Allocca M, Chaparro M, Gonzalez HA, Bosca-Watts MM, Palmela C, D'Amico F, Zacharopoulou E, Kopylov U, Ellul P, Bamias G, Ntelis V, Lahat A, Mantzaris GJ, Papaconstantinou I, Katsanos K, Uspenskaya Y, Christodoulou D, Ben Horin S, Peyrin-Biroulet L, Torres J, Sebastian S, Gisbert JP, Danese S, Fiorino G. Patients with Inflammatory Bowel Disease Are Not at Increased Risk of COVID-19: A Large Multinational Cohort Study. J Clin Med. 2020;9. [PMID: 33142843 DOI: 10.3390/jcm9113533] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
286 Shah R, Wright E, Tambakis G, Holmes J, Thompson A, Connell W, Lust M, Niewiadomski O, Kamm M, Basnayake C, Ding J. Telehealth model of care for outpatient inflammatory bowel disease care in the setting of the COVID-19 pandemic. Intern Med J 2021;51:1038-42. [PMID: 34278693 DOI: 10.1111/imj.15168] [Reference Citation Analysis]
287 Hadi Y, Dulai PS, Kupec J, Mohy-Ud-Din N, Jairath V, Farraye FA, Kochhar GS. Incidence, outcomes, and impact of COVID-19 on inflammatory bowel disease: Propensity matched research network analysis. Aliment Pharmacol Ther 2021. [PMID: 34904240 DOI: 10.1111/apt.16730] [Reference Citation Analysis]
288 Iborra I, Puig M, Marín L, Calafat M, Cañete F, Quiñones C, González-González L, Cardona G, Mañosa M, Domènech E. Treatment Adherence and Clinical Outcomes of Patients with Inflammatory Bowel Disease on Biological Agents During the SARS-CoV-2 Pandemic. Dig Dis Sci 2021. [PMID: 33469807 DOI: 10.1007/s10620-020-06807-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
289 Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 2021;18:56-66. [PMID: 33033392 DOI: 10.1038/s41575-020-00360-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 14.5] [Reference Citation Analysis]
290 Giesen N, Sprute R, Rüthrich M, Khodamoradi Y, Mellinghoff SC, Beutel G, Lueck C, Koldehoff M, Hentrich M, Sandherr M, von Bergwelt-Baildon M, Wolf HH, Hirsch HH, Wörmann B, Cornely OA, Köhler P, Schalk E, von Lilienfeld-Toal M. Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Eur J Cancer 2020;140:86-104. [PMID: 33068941 DOI: 10.1016/j.ejca.2020.09.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
291 Beecker J, Papp KA, Dutz J, Vender RB, Gniadecki R, Cooper C, Gisondi P, Gooderham M, Hong CH, Kirchhof MG, Lynde CW, Maari C, Poulin Y, Puig L. Position statement for a pragmatic approach to immunotherapeutics in patients with inflammatory skin diseases during the coronavirus disease 2019 pandemic and beyond. J Eur Acad Dermatol Venereol 2021;35:797-806. [PMID: 33533553 DOI: 10.1111/jdv.17075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
292 Cillo AR, Somasundaram A, Shan F, Cardello C, Workman CJ, Kitsios GD, Ruffin A, Kunning S, Lampenfeld C, Onkar S, Grebinoski S, Deshmukh G, Methe B, Liu C, Nambulli S, Andrews L, Duprex WP, Joglekar AV, Benos PV, Ray P, Ray A, McVerry BJ, Zhang Y, Lee JS, Das J, Singh H, Morris A, Bruno TC, Vignali DAA. Bifurcated monocyte states are predictive of mortality in severe COVID-19. bioRxiv 2021:2021. [PMID: 33594364 DOI: 10.1101/2021.02.10.430499] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
293 Yang Y, Luo K, Jiang Y, Yu Q, Huang X, Wang J, Liu N, Huang P. The Impact of Frailty on COVID-19 Outcomes: A Systematic Review and Meta-analysis of 16 Cohort Studies. J Nutr Health Aging 2021;25:702-9. [PMID: 33949641 DOI: 10.1007/s12603-021-1611-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
294 Levy E, Stintzi A, Cohen A, Desjardins Y, Marette A, Spahis S. Critical appraisal of the mechanisms of gastrointestinal and hepatobiliary infection by COVID-19. Am J Physiol Gastrointest Liver Physiol 2021;321:G99-G112. [PMID: 34009033 DOI: 10.1152/ajpgi.00106.2021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
295 Cohen-Mekelburg S, Wallace BI, Van T, Wiitala WL, Govani SM, Burns J, Lipson R, Yun H, Hou J, Lewis JD, Dominitz JA, Waljee AK. Association of Anti-Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease. JAMA Netw Open 2021;4:e210313. [PMID: 33646314 DOI: 10.1001/jamanetworkopen.2021.0313] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
296 Segal JP, Moss AC. Implications of recurrent SARS-CoV-2 outbreaks for IBD management. Frontline Gastroenterol 2021;12:316-21. [PMID: 34249317 DOI: 10.1136/flgastro-2020-101531] [Reference Citation Analysis]
297 Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, van Bentum-Puijk W, Berry L, Bhimani Z, Bonten M, Bradbury C, Brunkhorst F, Buxton M, Buzgau A, Cheng AC, de Jong M, Detry M, Estcourt L, Fitzgerald M, Goossens H, Green C, Haniffa R, Higgins AM, Horvat C, Hullegie SJ, Kruger P, Lamontagne F, Lawler PR, Linstrum K, Litton E, Lorenzi E, Marshall J, McAuley D, McGlothin A, McGuinness S, McVerry B, Montgomery S, Mouncey P, Murthy S, Nichol A, Parke R, Parker J, Rowan K, Sanil A, Santos M, Saunders C, Seymour C, Turner A, van de Veerdonk F, Venkatesh B, Zarychanski R, Berry S, Lewis RJ, McArthur C, Webb SA, Gordon AC, Al-Beidh F, Angus D, Annane D, Arabi Y, van Bentum-Puijk W, Berry S, Beane A, Bhimani Z, Bonten M, Bradbury C, Brunkhorst F, Buxton M, Cheng A, De Jong M, Derde L, Estcourt L, Goossens H, Gordon A, Green C, Haniffa R, Lamontagne F, Lawler P, Litton E, Marshall J, McArthur C, McAuley D, McGuinness S, McVerry B, Montgomery S, Mouncey P, Murthy S, Nichol A, Parke R, Rowan K, Seymour C, Turner A, van de Veerdonk F, Webb S, Zarychanski R, Campbell L, Forbes A, Gattas D, Heritier S, Higgins L, Kruger P, Peake S, Presneill J, Seppelt I, Trapani T, Young P, Bagshaw S, Daneman N, Ferguson N, Misak C, Santos M, Hullegie S, Pletz M, Rohde G, Rowan K, Alexander B, Basile K, Girard T, Horvat C, Huang D, Linstrum K, Vates J, Beasley R, Fowler R, McGloughlin S, Morpeth S, Paterson D, Venkatesh B, Uyeki T, Baillie K, Duffy E, Fowler R, Hills T, Orr K, Patanwala A, Tong S, Netea M, Bihari S, Carrier M, Fergusson D, Goligher E, Haidar G, Hunt B, Kumar A, Laffan M, Lawless P, Lother S, McCallum P, Middeldopr S, McQuilten Z, Neal M, Pasi J, Schutgens R, Stanworth S, Turgeon A, Weissman A, Adhikari N, Anstey M, Brant E, de Man A, Lamonagne F, Masse MH, Udy A, Arnold D, Begin P, Charlewood R, Chasse M, Coyne M, Cooper J, Daly J, Gosbell I, Harvala-Simmonds H, Hills T, MacLennan S, Menon D, McDyer J, Pridee N, Roberts D, Shankar-Hari M, Thomas H, Tinmouth A, Triulzi D, Walsh T, Wood E, Calfee C, O’Kane C, Shyamsundar M, Sinha P, Thompson T, Young I, Bihari S, Hodgson C, Laffey J, McAuley D, Orford N, Neto A, Detry M, Fitzgerald M, Lewis R, McGlothlin A, Sanil A, Saunders C, Berry L, Lorenzi E, Miller E, Singh V, Zammit C, van Bentum Puijk W, Bouwman W, Mangindaan Y, Parker L, Peters S, Rietveld I, Raymakers K, Ganpat R, Brillinger N, Markgraf R, Ainscough K, Brickell K, Anjum A, Lane JB, Richards-Belle A, Saull M, Wiley D, Bion J, Connor J, Gates S, Manax V, van der Poll T, Reynolds J, van Beurden M, Effelaar E, Schotsman J, Boyd C, Harland C, Shearer A, Wren J, Clermont G, Garrard W, Kalchthaler K, King A, Ricketts D, Malakoutis S, Marroquin O, Music E, Quinn K, Cate H, Pearson K, Collins J, Hanson J, Williams P, Jackson S, Asghar A, Dyas S, Sutu M, Murphy S, Williamson D, Mguni N, Potter A, Porter D, Goodwin J, Rook C, Harrison S, Williams H, Campbell H, Lomme K, Williamson J, Sheffield J, van’t Hoff W, McCracken P, Young M, Board J, Mart E, Knott C, Smith J, Boschert C, Affleck J, Ramanan M, D’Souza R, Pateman K, Shakih A, Cheung W, Kol M, Wong H, Shah A, Wagh A, Simpson J, Duke G, Chan P, Cartner B, Hunter S, Laver R, Shrestha T, Regli A, Pellicano A, McCullough J, Tallott M, Kumar N, Panwar R, Brinkerhoff G, Koppen C, Cazzola F, Brain M, Mineall S, Fischer R, Biradar V, Soar N, White H, Estensen K, Morrison L, Smith J, Cooper M, Health M, Shehabi Y, Al-Bassam W, Hulley A, Whitehead C, Lowrey J, Gresha R, Walsham J, Meyer J, Harward M, Venz E, Williams P, Kurenda C, Smith K, Smith M, Garcia R, Barge D, Byrne D, Byrne K, Driscoll A, Fortune L, Janin P, Yarad E, Hammond N, Bass F, Ashelford A, Waterson S, Wedd S, McNamara R, Buhr H, Coles J, Schweikert S, Wibrow B, Rauniyar R, Myers E, Fysh E, Dawda A, Mevavala B, Litton E, Ferrier J, Nair P, Buscher H, Reynolds C, Santamaria J, Barbazza L, Homes J, Smith R, Murray L, Brailsford J, Forbes L, Maguire T, Mariappa V, Smith J, Simpson S, Maiden M, Bone A, Horton M, Salerno T, Sterba M, Geng W, Depuydt P, De Waele J, De Bus L, Fierens J, Bracke S, Reeve B, Dechert W, Chassé M, Carrier FM, Boumahni D, Benettaib F, Ghamraoui A, Bellemare D, Cloutier È, Francoeur C, Lamontagne F, D’Aragon F, Carbonneau E, Leblond J, Vazquez-Grande G, Marten N, Wilson M, Albert M, Serri K, Cavayas A, Duplaix M, Williams V, Rochwerg B, Karachi T, Oczkowski S, Centofanti J, Millen T, Duan E, Tsang J, Patterson L, English S, Watpool I, Porteous R, Miezitis S, McIntyre L, Brochard L, Burns K, Sandhu G, Khalid I, Binnie A, Powell E, McMillan A, Luk T, Aref N, Andric Z, Cviljevic S, Đimoti R, Zapalac M, Mirković G, Baršić B, Kutleša M, Kotarski V, Vujaklija Brajković A, Babel J, Sever H, Dragija L, Kušan I, Vaara S, Pettilä L, Heinonen J, Kuitunen A, Karlsson S, Vahtera A, Kiiski H, Ristimäki S, Azaiz A, Charron C, Godement M, Geri G, Vieillard-Baron A, Pourcine F, Monchi M, Luis D, Mercier R, Sagnier A, Verrier N, Caplin C, Siami S, Aparicio C, Vautier S, Jeblaoui A, Fartoukh M, Courtin L, Labbe V, Leparco C, Muller G, Nay MA, Kamel T, Benzekri D, Jacquier S, Mercier E, Chartier D, Salmon C, Dequin P, Schneider F, Morel G, L’Hotellier S, Badie J, Berdaguer FD, Malfroy S, Mezher C, Bourgoin C, Megarbane B, Voicu S, Deye N, Malissin I, Sutterlin L, Guitton C, Darreau C, Landais M, Chudeau N, Robert A, Moine P, Heming N, Maxime V, Bossard I, Nicholier TB, Colin G, Zinzoni V, Maquigneau N, Finn A, Kreß G, Hoff U, Friedrich Hinrichs C, Nee J, Pletz M, Hagel S, Ankert J, Kolanos S, Bloos F, Petros S, Pasieka B, Kunz K, Appelt P, Schütze B, Kluge S, Nierhaus A, Jarczak D, Roedl K, Weismann D, Frey A, Klinikum Neukölln V, Reill L, Distler M, Maselli A, Bélteczki J, Magyar I, Fazekas Á, Kovács S, Szőke V, Szigligeti G, Leszkoven J, Collins D, Breen P, Frohlich S, Whelan R, McNicholas B, Scully M, Casey S, Kernan M, Doran P, O’Dywer M, Smyth M, Hayes L, Hoiting O, Peters M, Rengers E, Evers M, Prinssen A, Bosch Ziekenhuis J, Simons K, Rozendaal W, Polderman F, de Jager P, Moviat M, Paling A, Salet A, Rademaker E, Peters AL, de Jonge E, Wigbers J, Guilder E, Butler M, Cowdrey KA, Newby L, Chen Y, Simmonds C, McConnochie R, Ritzema Carter J, Henderson S, Van Der Heyden K, Mehrtens J, Williams T, Kazemi A, Song R, Lai V, Girijadevi D, Everitt R, Russell R, Hacking D, Buehner U, Williams E, Browne T, Grimwade K, Goodson J, Keet O, Callender O, Martynoga R, Trask K, Butler A, Schischka L, Young C, Lesona E, Olatunji S, Robertson Y, José N, Amaro dos Santos Catorze T, de Lima Pereira TNA, Neves Pessoa LM, Castro Ferreira RM, Pereira Sousa Bastos JM, Aysel Florescu S, Stanciu D, Zaharia MF, Kosa AG, Codreanu D, Marabi Y, Al Qasim E, Moneer Hagazy M, Al Swaidan L, Arishi H, Muñoz-Bermúdez R, Marin-Corral J, Salazar Degracia A, Parrilla Gómez F, Mateo López MI, Rodriguez Fernandez J, Cárcel Fernández S, Carmona Flores R, León López R, de la Fuente Martos C, Allan A, Polgarova P, Farahi N, McWilliam S, Hawcutt D, Rad L, O’Malley L, Whitbread J, Kelsall O, Wild L, Thrush J, Wood H, Austin K, Donnelly A, Kelly M, O’Kane S, McClintock D, Warnock M, Johnston P, Gallagher LJ, Mc Goldrick C, Mc Master M, Strzelecka A, Jha R, Kalogirou M, Ellis C, Krishnamurthy V, Deelchand V, Silversides J, McGuigan P, Ward K, O’Neill A, Finn S, Phillips B, Mullan D, Oritz-Ruiz de Gordoa L, Thomas M, Sweet K, Grimmer L, Johnson R, Pinnell J, Robinson M, Gledhill L, Wood T, Morgan M, Cole J, Hill H, Davies M, Antcliffe D, Templeton M, Rojo R, Coghlan P, Smee J, Mackay E, Cort J, Whileman A, Spencer T, Spittle N, Kasipandian V, Patel A, Allibone S, Genetu RM, Ramali M, Ghosh A, Bamford P, London E, Cawley K, Faulkner M, Jeffrey H, Smith T, Brewer C, Gregory J, Limb J, Cowton A, O’Brien J, Nikitas N, Wells C, Lankester L, Pulletz M, Williams P, Birch J, Wiseman S, Horton S, Alegria A, Turki S, Elsefi T, Crisp N, Allen L, McCullagh I, Robinson P, Hays C, Babio-Galan M, Stevenson H, Khare D, Pinder M, Selvamoni S, Gopinath A, Pugh R, Menzies D, Mackay C, Allan E, Davies G, Puxty K, McCue C, Cathcart S, Hickey N, Ireland J, Yusuff H, Isgro G, Brightling C, Bourne M, Craner M, Watters M, Prout R, Davies L, Pegler S, Kyeremeh L, Arbane G, Wilson K, Gomm L, Francia F, Brett S, Sousa Arias S, Elin Hall R, Budd J, Small C, Birch J, Collins E, Henning J, Bonner S, Hugill K, Cirstea E, Wilkinson D, Karlikowski M, Sutherland H, Wilhelmsen E, Woods J, North J, Sundaran D, Hollos L, Coburn S, Walsh J, Turns M, Hopkins P, Smith J, Noble H, Depante MT, Clarey E, Laha S, Verlander M, Williams A, Huckle A, Hall A, Cooke J, Gardiner-Hill C, Maloney C, Qureshi H, Flint N, Nicholson S, Southin S, Nicholson A, Borgatta B, Turner-Bone I, Reddy A, Wilding L, Chamara Warnapura L, Agno Sathianathan R, Golden D, Hart C, Jones J, Bannard-Smith J, Henry J, Birchall K, Pomeroy F, Quayle R, Makowski A, Misztal B, Ahmed I, KyereDiabour T, Naiker K, Stewart R, Mwaura E, Mew L, Wren L, Willams F, Innes R, Doble P, Hutter J, Shovelton C, Plumb B, Szakmany T, Hamlyn V, Hawkins N, Lewis S, Dell A, Gopal S, Ganguly S, Smallwood A, Harris N, Metherell S, Lazaro JM, Newman T, Fletcher S, Nortje J, Fottrell-Gould D, Randell G, Zaman M, Elmahi E, Jones A, Hall K, Mills G, Ryalls K, Bowler H, Sall J, Bourne R, Borrill Z, Duncan T, Lamb T, Shaw J, Fox C, Moreno Cuesta J, Xavier K, Purohit D, Elhassan M, Bakthavatsalam D, Rowland M, Hutton P, Bashyal A, Davidson N, Hird C, Chhablani M, Phalod G, Kirkby A, Archer S, Netherton K, Reschreiter H, Camsooksai J, Patch S, Jenkins S, Pogson D, Rose S, Daly Z, Brimfield L, Claridge H, Parekh D, Bergin C, Bates M, Dasgin J, McGhee C, Sim M, Hay SK, Henderson S, Phull MK, Zaidi A, Pogreban T, Rosaroso LP, Harvey D, Lowe B, Meredith M, Ryan L, Hormis A, Walker R, Collier D, Kimpton S, Oakley S, Rooney K, Rodden N, Hughes E, Thomson N, McGlynn D, Walden A, Jacques N, Coles H, Tilney E, Vowell E, Schuster-Bruce M, Pitts S, Miln R, Purandare L, Vamplew L, Spivey M, Bean S, Burt K, Moore L, Day C, Gibson C, Gordon E, Zitter L, Keenan S, Baker E, Cherian S, Cutler S, Roynon-Reed A, Harrington K, Raithatha A, Bauchmuller K, Ahmad N, Grecu I, Trodd D, Martin J, Wrey Brown C, Arias AM, Craven T, Hope D, Singleton J, Clark S, Rae N, Welters I, Hamilton DO, Williams K, Waugh V, Shaw D, Puthucheary Z, Martin T, Santos F, Uddin R, Somerville A, Tatham KC, Jhanji S, Black E, Dela Rosa A, Howle R, Tully R, Drummond A, Dearden J, Philbin J, Munt S, Vuylsteke A, Chan C, Victor S, Matsa R, Gellamucho M, Creagh-Brown B, Tooley J, Montague L, De Beaux F, Bullman L, Kersiake I, Demetriou C, Mitchard S, Ramos L, White K, Donnison P, Johns M, Casey R, Mattocks L, Salisbury S, Dark P, Claxton A, McLachlan D, Slevin K, Lee S, Hulme J, Joseph S, Kinney F, Senya HJ, Oborska A, Kayani A, Hadebe B, Orath Prabakaran R, Nichols L, Thomas M, Worner R, Faulkner B, Gendall E, Hayes K, Hamilton-Davies C, Chan C, Mfuko C, Abbass H, Mandadapu V, Leaver S, Forton D, Patel K, Paramasivam E, Powell M, Gould R, Wilby E, Howcroft C, Banach D, Fernández de Pinedo Artaraz Z, Cabreros L, White I, Croft M, Holland N, Pereira R, Zaki A, Johnson D, Jackson M, Garrard H, Juhaz V, Roy A, Rostron A, Woods L, Cornell S, Pillai S, Harford R, Rees T, Ivatt H, Sundara Raman A, Davey M, Lee K, Barber R, Chablani M, Brohi F, Jagannathan V, Clark M, Purvis S, Wetherill B, Dushianthan A, Cusack R, de Courcy-Golder K, Smith S, Jackson S, Attwood B, Parsons P, Page V, Zhao XB, Oza D, Rhodes J, Anderson T, Morris S, Xia Le Tai C, Thomas A, Keen A, Digby S, Cowley N, Wild L, Southern D, Reddy H, Campbell A, Watkins C, Smuts S, Touma O, Barnes N, Alexander P, Felton T, Ferguson S, Sellers K, Bradley-Potts J, Yates D, Birkinshaw I, Kell K, Marshall N, Carr-Knott L, Summers C; Writing Committee for the REMAP-CAP Investigators. Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial. JAMA 2020;324:1317-29. [PMID: 32876697 DOI: 10.1001/jama.2020.17022] [Cited by in Crossref: 228] [Cited by in F6Publishing: 223] [Article Influence: 114.0] [Reference Citation Analysis]
298 Di Ruscio M, Lunardi G, Buonfrate D, Gobbi F, Bertoli G, Piccoli D, Conti A, Geccherle A, Variola A. A Seroprevalence Study of Anti-SARS-CoV-2 Antibodies in Patients with Inflammatory Bowel Disease during the Second Wave of the COVID-19 Pandemic in Italy. Medicina (Kaunas) 2021;57:1048. [PMID: 34684085 DOI: 10.3390/medicina57101048] [Reference Citation Analysis]
299 Sperger J, Shah KS, Lu M, Zhang X, Ungaro RC, Brenner EJ, Agrawal M, Colombel JF, Kappelman MD, Kosorok MR. Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD. BMJ Open 2021;11:e049740. [PMID: 34772750 DOI: 10.1136/bmjopen-2021-049740] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
300 Zhang H, Ma S, Han T, Qu G, Cheng C, Uy JP, Shaikh MB, Zhou Q, Song EJ, Sun C. Association of smoking history with severe and critical outcomes in COVID-19 patients: A systemic review and meta-analysis.Eur J Integr Med. 2021;43:101313. [PMID: 33619437 DOI: 10.1016/j.eujim.2021.101313] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
301 Prentice RE, Al-Ani A, Christensen B. Managing COVID-19 in patients with inflammatory bowel disease: navigating unprecedented challenges. Intern Med J 2021;51:284-7. [PMID: 33631857 DOI: 10.1111/imj.15190] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
302 Feitosa MR, Parra RS, de Camargo HP, Ferreira SDC, Troncon LEA, da Rocha JJR, Féres O. COVID-19 quarantine measures are associated with negative social impacts and compromised follow-up care in patients with inflammatory bowel disease in Brazil. Ann Gastroenterol 2021;34:39-45. [PMID: 33414620 DOI: 10.20524/aog.2020.0558] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
303 Li R, Chen C, Liu B, Shi W, Shimizu K, Zhang C. Bryodulcosigenin a natural cucurbitane-type triterpenoid attenuates dextran sulfate sodium (DSS)-induced colitis in mice. Phytomedicine 2022;94:153814. [PMID: 34798522 DOI: 10.1016/j.phymed.2021.153814] [Reference Citation Analysis]
304 Robinson PC, Bursle EC; Senior staff specialist2., Infectious diseases physician3., Clinical microbiologist34. Management of autoimmune disease during the COVID-19 pandemic. Aust Prescr 2020;43:146-7. [PMID: 33093739 DOI: 10.18773/austprescr.2020.058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
305 Nardone OM, Rispo A, Testa A, Imperatore N, Pellegrini L, Guarino AD, Ricciolino S, Patturelli M, De Palma G, Castiglione F. The impact of a dedicated contact centre on the clinical outcome of patients with inflammatory bowel disease during the COVID-19 outbreak. Therap Adv Gastroenterol 2020;13:1756284820959586. [PMID: 33024453 DOI: 10.1177/1756284820959586] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
306 Johnson SD, Olwenyi OA, Bhyravbhatla N, Thurman M, Pandey K, Klug EA, Johnston M, Dyavar SR, Acharya A, Podany AT, Fletcher CV, Mohan M, Singh K, Byrareddy SN. Therapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axis. World J Gastroenterol 2021; 27(29): 4763-4783 [PMID: 34447225 DOI: 10.3748/wjg.v27.i29.4763] [Reference Citation Analysis]
307 Prentice RE, Rentsch C, Al-Ani AH, Zhang E, Johnson D, Halliday J, Bryant R, Begun J, Ward MG, Lewindon PJ, Connor SJ, Ghaly S, Christensen B. SARS-CoV-2 vaccination in patients with inflammatory bowel disease. GastroHep 2021;3:212-28. [PMID: 34539248 DOI: 10.1002/ygh2.473] [Reference Citation Analysis]
308 Efe C, Dhanasekaran R, Lammert C, Ebik B, Higuera-de la Tijera F, Aloman C, Rıza Calışkan A, Peralta M, Gerussi A, Massoumi H, Catana AM, Torgutalp M, Purnak T, Rigamonti C, Gomez Aldana AJ, Khakoo N, Kacmaz H, Nazal L, Frager S, Demir N, Irak K, Ellik ZM, Balaban Y, Atay K, Eren F, Cristoferi L, Batıbay E, Urzua Á, Snijders R, Kıyıcı M, Akyıldız M, Ekin N, Carr RM, Harputluoğlu M, Hatemi I, Mendizabal M, Silva M, Idilman R, Silveira M, Drenth JPH, Assis DN, Björnsson E, Boyer JL, Invernizzi P, Levy C, Schiano TD, Ridruejo E, Wahlin S. Outcome of COVID-19 in Patients With Autoimmune Hepatitis: An International Multicenter Study. Hepatology 2021;73:2099-109. [PMID: 33713486 DOI: 10.1002/hep.31797] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
309 Navaneethan U, Lourdusamy D, LehnerNoguera V, Shen B. Safety of Endoscopy in Patients With Inflammatory Bowel Disease During the COVID-19 Pandemic. Inflamm Bowel Dis 2020;26:e118-9. [PMID: 32676646 DOI: 10.1093/ibd/izaa192] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
310 Wall D, Alhusayen R, Arents B, Apfelbacher C, Balogh EA, Bokhari L, Bloem M, Bosma AL, Burton T, Castelo-Soccio L, Fagan N, Feldman SR, Fletcher G, Flohr C, Freeman E, French LE, Griffiths CEM, Hruza GJ, Ingram JR, Kappelman MD, Lara-Corrales I, Lim HW, Meah N, McMahon DE, Mahil SK, McNicoll I, Musters A, Naik HB, Sinclair R, Smith CH, Spuls P, Tobin DJ, York K, Irvine AD. Learning from disease registries during a pandemic: Moving toward an international federation of patient registries. Clin Dermatol 2021;39:467-78. [PMID: 34518006 DOI: 10.1016/j.clindermatol.2021.01.018] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
311 Spinelli FR, Meylan F, O'Shea JJ, Gadina M. JAK inhibitors: Ten years after. Eur J Immunol 2021;51:1615-27. [PMID: 33930196 DOI: 10.1002/eji.202048922] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
312 Ashton JJ, Kammermeier J, Spray C, Russell RK, Hansen R, Howarth LJ, Torrente F, Deb P, Renji E, Muhammed R, Paul T, Kiparissi F, Epstein J, Lawson M, Hope B, Zamvar V, Narula P, Kadir A, Devadason D, Bhavsar H, Beattie RM. Impact of COVID-19 on diagnosis and management of paediatric inflammatory bowel disease during lockdown: a UK nationwide study. Arch Dis Child. 2020;105:1186-1191. [PMID: 32732316 DOI: 10.1136/archdischild-2020-319751] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
313 Zahedi Niaki O, Anadkat MJ, Chen ST, Fox LP, Harp J, Micheletti RG, Nambudiri VE, Pasieka HB, Shinohara MM, Rosenbach M, Merola JF. Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. J Am Acad Dermatol 2020;83:1150-9. [PMID: 32569797 DOI: 10.1016/j.jaad.2020.06.051] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]
314 Taxonera C, Alba C, Olivares D. What is the incidence of COVID-19 in patients with IBD in western countries? Gastroenterology. 2020;. [PMID: 32687925 DOI: 10.1053/j.gastro.2020.05.099] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
315 Mak JWY, Weng MT, Wei SC, Ng SC. Zero COVID-19 infection in inflammatory bowel disease patients: Findings from population-based inflammatory bowel disease registries in Hong Kong and Taiwan. J Gastroenterol Hepatol 2021;36:171-3. [PMID: 32589798 DOI: 10.1111/jgh.15164] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
316 Mani I, Alexopoulou A. Recent challenges facing patients with preexisting chronic liver disease in the era of the COVID-19 pandemic. Ann Gastroenterol 2021;34:625-33. [PMID: 34475732 DOI: 10.20524/aog.2021.0628] [Reference Citation Analysis]
317 Negahdaripour M, Shafiekhani M, Moezzi SMI, Amiri S, Rasekh S, Bagheri A, Mosaddeghi P, Vazin A. Administration of COVID-19 vaccines in immunocompromised patients. Int Immunopharmacol 2021;99:108021. [PMID: 34352567 DOI: 10.1016/j.intimp.2021.108021] [Reference Citation Analysis]
318 Attauabi M, Seidelin J, Burisch J; Danish COVID-IBD Study Group. Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology? Gut 2021:gutjnl-2021-324397. [PMID: 33658323 DOI: 10.1136/gutjnl-2021-324397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
319 Goldman JD, Robinson PC, Uldrick TS, Ljungman P. COVID-19 in immunocompromised populations: implications for prognosis and repurposing of immunotherapies. J Immunother Cancer 2021;9:e002630. [PMID: 34117116 DOI: 10.1136/jitc-2021-002630] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
320 Queiroz NSF, Teixeira FV, Freire CCF, Motta MP, Vasconcellos MAM, Chebli LA, Saad-Hossne R; Brazilian Inflamatory Bowel Diseases Study Group (GEDIIB) COVID taskforce. BRAZILIAN IBD STUDY GROUP POSITION STATEMENT ON SARS-COV2 VACCINATION. Arq Gastroenterol 2021;58:1-4. [PMID: 33909805 DOI: 10.1590/S0004-2803.202100000-02] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
321 Kutsuna S. Clinical Manifestations of Coronavirus Disease 2019. JMA J 2021;4:76-80. [PMID: 33997439 DOI: 10.31662/jmaj.2021-0013] [Reference Citation Analysis]